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ABSTRACT
Opioid overdose deaths have quadrupled since 1999 (Centers for Disease Control and
Prevention, 2018c). Georgia is one of 35 states with a significant increase in drug overdose
deaths from 2013 – 2017 (Scholl et al., 2019), with deaths increasing by 70% during 2010-2018
(Georgia Department of Public Health, 2018). Many states, including Georgia, have
implemented naloxone standing orders to remove barriers to access to naloxone, an opioid
overdose reversal drug that reverses opioid overdose symptoms. However, it is still not readily
available in places where it is most needed. This research investigates naloxone availability in
Georgia 44 months after the implementation of a statewide standing order. This research also
seeks to determine if pharmacy and community-level factors are associated with naloxone
availability. A stratified random sample of active retail pharmacies based on USDA Rural-Urban
Continuum Codes was surveyed by phone using a simulated client methodology to gather
information about naloxone availability. Chi-square analyses were conducted on each factor to
assess associations with naloxone availability. A multiple logistic regression analysis was then
conducted to explore further factors associated with availability and their ability to predict
naloxone availability in a combined model. Results showed that pharmacy type and political
leaning were both associated with and were statistically significant in predicting naloxone
availability in Georgia. Pharmacy and community-level variables included in this study produced

a statistically significant model to predict naloxone availability. Naloxone availability continues
to be a vital harm reduction tool in preventing opioid overdoses. Pharmacies in Georgia are
critical in providing statewide access to naloxone. Opportunities remain to understand better
standing order implementation, factors that influence implementation, and opportunities to
improve naloxone availability.
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CHAPTER 1
INTRODUCTION
Overview of the Opioid Epidemic
Opioid overdose has become a major public health concern within the past decade, with
192 people dying every day from opioid overdoses (Centers for Disease Control and
Prevention, 2019). Opioid overdose deaths have quadrupled since 1999 (Centers for Disease
Control and Prevention, 2018c). Drug overdoses have resulted in 702,568 deaths in the U.S.
since 1999, with more than half of the deaths (56.8%) involving opioids (Scholl et al., 2019).
Synthetic opioids were involved in 59.8% of all opioid-involved overdose deaths, a rate
increase of 45.2% from 2016 to 2017 (Scholl et al., 2019). U.S. life expectancy declined for
three consecutive years, mostly because of the rise in opioid overdose deaths (Centers for
Disease Control and Prevention, 2018b). Every state has been affected by this public health
epidemic. From 2013 to 2017, drug overdose death rates increased in most states, with the
influence of synthetic opioids on rate increases seen in about one-quarter of all states (Scholl et
al., 2019).
Although recent data shows deaths continue to increase (Scholl et al., 2019), the impact of
opioid use on Americans is not a new phenomenon. CDC describes three waves to characterize
the epidemic. The first wave began in the 1990s with increased prescribing and use of
prescription opioids (Centers for Disease Control and Prevention, 2018c) and aggressive
marketing of opioids for pain management (Baker, 2017). The second wave of the epidemic
began in 2010 as overdose deaths involving heroin increased (Centers for Disease Control and
Prevention, 2018c). During this time, prescription opioid use began to decrease, and illicit drug
use increased (Centers for Disease Control and Prevention, 2018c). This increase marked the
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beginnings of another shift in the epidemic with increasing deaths involving synthetic opioids
such as illicitly manufactured fentanyl (O’Donnell et al., 2017). Significant rises in overdose
deaths involving synthetic opioids (such as illicitly manufactured fentanyl) have been as recent
as 2013 (Centers for Disease Control and Prevention, 2018c). Figure 1.1 depicts the waves of the
epidemic from 1999 to 2018.

Figure 1.1
Waves of the Rise in Opioid Overdose Deaths

Note. Figure adapted from 3 Waves of the Rise in Opioid Overdose Deaths, by U.S. Centers for Disease Control and
Prevention, 2018 (https://www.cdc.gov/drugoverdose/images/epidemic/2018-3-Wave-Lines-Mortality.png). In the
public domain.
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Mortality data demonstrate the toll opioid overdoses have had on the country. Georgia is
one of 35 states with a significant increase in drug overdose deaths from 2013 to 2017 (Scholl et
al., 2019), with deaths increasing by 70% from 2010 to 2018 (Georgia Department of Public
Health, 2018). Figure 1.2 shows five-year overdose death rates across the state during 2014 –
2018. Morbidity data continues to demonstrate the burden of opioid overdoses in Georgia. In
2018, the highest number of emergency department visits and hospitalizations were found in
both urban and rural areas of the state but were highest in North, South Central, and Southeast
Georgia (Georgia Department of Public Health, 2018).

Figure 1.2
Georgia Opioid Death Rates by County, 2014 – 2018

Note. From Georgia Department of Public Health. (2020). Division of Public Health, Online Analytical Statistical
Information System (OASIS). Retrieved from https://oasis.state.ga.us/gis/TrendableMaps/agsDrugODTrend.aspx
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Nationally, public health practitioners have taken many actions to address the opioid
overdose epidemic. The CDC declared an opioid epidemic in 2011, with the Office of National
Drug Control Policy (ONDCP) releasing a plan to address the opioid epidemic across the
government the same year (Bipartisan Policy Center, 2019). In 2017, the White House declared
the opioid crisis a public health emergency (U. S. Department of Health and Human Services,
2017). This decade also brought with it increased funding from various federal agencies to
support states in combating the epidemic (Bipartisan Policy Center, 2019). With national efforts
to combat this epidemic, it is crucial to identify how those activities are being implemented in
communities across the country.
What is Naloxone?
Naloxone is a lifesaving drug that, if given in time, can allow more time for emergency
personnel to intervene. It acts to reverse overdose symptoms by binding to opioid receptors and
reversing or blocking the effects of opioids (Substance Abuse and Mental Health Services
Administration, 2019). This drug works to restore normal breathing in people that have either
slowed or stopped breathing due to opioid use (National Institute on Drug Abuse, 2014).
Naloxone has no abuse or recreational use potential (Chamberlain & Klein, 1994), making it
ideal to have on hand in case of an overdose event. Naloxone has also been shown to effectively
reduce opioid overdose mortality rates (Haegerich et al., 2014). However, it is not readily
available in places where it is most needed. Naloxone is the low-hanging fruit of overdose
prevention, capable of saving innumerable lives at a relatively low cost (Davis & Carr 2015).
Until recently, naloxone has historically been distributed through community overdose education
and naloxone distribution (OEND) programs or administered by health care personnel (Wheeler
et al., 2015). Increasing calls to improve naloxone availability indicate this drug’s vital role in
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combatting the opioid epidemic. Availability and utilization of naloxone is one of three priority
target areas identified by the HHS Secretary to combat the opioid overdose epidemic (U.S.
Department of Health and Human Services, 2015). HHS’s strategy to combat opioid abuse,
misuse, and overdose includes, as one of its five points, focused strategies on improving
widespread availability of naloxone (U. S. Department of Health and Human Services, 2018). In
2018, the Surgeon General released an advisory promoting the use of naloxone in preventing
opioid overdose deaths (Office of the Surgeon General, 2018).
Naloxone Access Policies
To prevent prescription drug overdose and abuse, many states have implemented
naloxone access policies to provide access to a lifesaving drug that reverse overdose symptoms.
One policy effort includes expanding both access to and distribution of naloxone. Unlike other
medications used to address opioid addiction, it is the only drug available that reverses physical
symptoms of an opioid overdose. Other medications work to block the effects of opioids before
they are felt. As of 2017, all states and Washington D.C. have policies in place to provide
improved access to and remove legal barriers naloxone, to include good samaritan laws, laws
removing criminal and civil liability related to prescribing and dispensing naloxone, and laws
giving people direct access to naloxone without a patient-specific prescription. As of 2017, 49
states and the District of Columbia allow people to access naloxone either through 3rd party
prescriptions (given to people that are close to those that may overdose) or standing orders
(allowing anyone to obtain naloxone in a pharmacy under a blanket prescription) (Prescription
Drug Abuse Policy System, 2017). Standing orders are of significant benefit because they
facilitate access to naloxone and remove barriers to naloxone access, including law and policy
barriers, the need for a person-specific prescription, and access outside of traditional sources
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(OEND and health care settings), and increased availability. Laws and policies have been a
barrier because they restrict access to this life-saving drug due to requirements for prescribing
and practice laws that discourage dispensing drugs to a person other than the intended recipient
(Davis et al., 2013). Standing orders address this law and policy barrier by removing the
requirement and need for a person-specific prescription. Standing orders also improve access to
naloxone outside of traditional health care and OEND programs as they provide an avenue to
access naloxone through other health care settings, such as pharmacies. Pharmacy access to
naloxone increases access because it provides wider geographic access in places with limited
healthcare providers. This improved access can help people who do not regularly access the
traditional health care system (such as illicit users).
Policy History in Georgia
House Bill 965, the Georgia 911 Medical Amnesty Law, was signed into law on April 24,
2014, to expand access to naloxone and provide legal protections for good samaritans and health
care providers ("Georgia 911 medical amnesty law," 2014). This law authorized the following: 1)
administration of naloxone by trained first responders (law enforcement, firefighters, EMS
personnel) for overdose reversal; 2) good faith naloxone prescription-writing by medical
professionals to those at risk of opioid-related overdose; 3) naloxone administration by laypeople
to persons suspected of experiencing an opioid overdose; and 4) protection from arrest and
prosecution for people who call 911 seeking medical assistance for those experiencing alcohol or
other drug-related overdoses. Authorizing prescribing and administration and removing legal
barriers were important because quickly administering naloxone is essential in reversing opioid
overdoses. The quick administration of naloxone is important in decreasing the likelihood that a
person dies from an overdose. However, a person-specific prescription was still required as a
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provision of the law. Three years later, on January 13, 2017, Dr. Brenda Fitzgerald, the
Commissioner of Public Health, signed into effect Georgia’s standing order for naloxone,
allowing for access in a retail pharmacy without a patient-specific prescription (Georgia
Department of Public Health, 2017). This standing order provided access to four types of
naloxone: two intramuscular versions, administered manually or automatically into the muscle
with a needle, and two intranasal spray versions. On April 18, 2017, Governor Nathan Deal
signed into the law the Jeffrey Dallas Gay, Jr. Act, codifying expanded access to naloxone
through the state’s standing order ("Jeffrey dallas gay, jr. Act," 2017). The Act also removed
civil and criminal liability to dispensers (i.e., pharmacists) in the state. Access to naloxone
through the standing order is a valuable policy strategy in the toolbox of harm reduction
strategies put into place to address the opioid epidemic in Georgia as it removes the need for a
person-specific prescription and provides extended access to people that may not encounter the
health care system in other ways.
Research Purpose
This research aims to provide more information around naloxone availability in retail
pharmacies in the state of Georgia. It is important to add to the scientific literature to discuss the
outcomes of policies implemented to combat the opioid epidemic. Effective policy
implementation is an important strategy in improving health outcomes across public health
topics. This research is intended to benefit practitioners in the state and inform future research
around standing order implementation. It is also meant to assist other states in possible factors
that influence naloxone standing order implementation and success.
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Research Questions and Hypotheses
Naloxone policies have been implemented as a harm reduction strategy to decrease
opioid overdose deaths by providing access to a drug that can reverse overdose symptoms. This
research intends to address two aims: 1) describe and explore naloxone availability in retail
pharmacies in Georgia 44 months after naloxone standing order implementation; and 2)
determine associations and develop a model to predict naloxone availability based on pharmacy
and community-level factors. The objective of the first research aim is to provide descriptive
data on naloxone availability 44 months after the passage of Georgia’s naloxone standing order,
describing differences based on county urbanicity, pharmacy type, county age-adjusted opioid
overdose death rates, county median household income, and county political leaning. Recent
work suggests that states with standing orders or third-party provisions saw a 79% increase in
naloxone prescriptions dispensed than states without these laws (Xu et al., 2018). However, the
impact of specific policies on opioid overdose deaths remains unknown (Freeman et al., 2018).
The second research aim research sought to determine associations between pharmacy and
community-level factors identified in the literature and naloxone availability and develop a
model for predicting availability based on those factors. Research questions and hypotheses are
as follows:
•

Research Question 1: What is the availability of naloxone in retail pharmacies 44
months after the implementation of Georgia’s naloxone standing order?
o Hypothesis 1: There will be a reported increase in naloxone availability
compared to previous research in Georgia.
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•

Research Question 2: What pharmacy and community-level factors are associated with
naloxone availability in retail pharmacies 44 months after the implementation of
Georgia’s naloxone standing order?
o Hypothesis 2: Naloxone availability is associated with pharmacy type.
o Hypothesis 3: Naloxone availability is associated with county rurality/urbanicity.
o Hypothesis 4: Naloxone availability is associated with high county overdose
death rates.
o Hypothesis 5: Naloxone availability is associated with county median household
income.
o Hypothesis 6: Naloxone availability is associated with county political
preferences (political leaning).

•

Research Question 3: How well can naloxone availability be predicted based on
pharmacy and community-level factors, to include rurality and urbanicity, retail
pharmacy type, county median household income, county age-adjusted opioid overdose
death rates, and county political leaning?
o Hypothesis 7A: Naloxone availability can be predicted based on retail pharmacy
type, rurality/urbanicity, opioid overdose deaths, median household income, and
political leaning.

Study Significance
Traditionally, naloxone distribution occurs primarily in community-based programs
(Jones et al., 2016), which provide access to populations that do not engage with the health care
system. The challenge with this is that it can be difficult to ensure diversity geographically with
an epidemic affecting all communities. Community distribution via pharmacies is a viable option
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to ensure wide distribution in affected communities. It complements the distribution conducted
by community-based organizations. Despite the reach of the epidemic to every corner of the
country, little empirical research has been conducted to determine actual availability following
standing order implementation. There is also very little published literature focused on
determining the relationship between standing orders, naloxone availability, and opioid overdose
death rates. Of those, only three studies focused on determining associations between standing
orders, naloxone availability, and community-level factors (Guadamuz et al., 2019; Lozo et al.,
2019; Meyerson et al., 2018). Two recently published studies describe naloxone availability in
Georgia. One investigates naloxone availability a few months after standing order
implementation (Stone et al., 2019). Another one focuses only on rural Georgia naloxone
availability (Nguyen et al., 2020). Although these two studies offer insight on naloxone
availability, recent naloxone availability is unknown, and comparisons between urban and rural
areas are needed. Geographically, there is limited literature published on standing order
implementation and naloxone availability in the southeastern United States. As of this writing,
few studies investigated naloxone availability through retail pharmacies in the southeastern
United States; North Carolina (Egan, Foster, Knudsen, & Lee, 2020b), Alabama (Sisson et al.,
2019), and Georgia (Nguyen et al., 2020; Stone et al., 2019).
This study seeks to provide information that could be used to evaluate and possibly
improve policy implementation. In theory, standing orders are put in place to provide easier
access to a drug. Limited research has been published to describe if that access exists in Georgia.
Outcomes from this research can assist public health practitioners in the state in understanding
the success of the statewide standing order, as increasing access to naloxone has been identified
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as one of Georgia’s most urgent need (Georgia Prevention Project, 2017). Additionally, it can
inform efforts in other states around naloxone access and factors that influence availability.
Delimitations
This study is limited to Georgia’s naloxone standing order. While a few studies have
looked at associations between naloxone laws and opioid overdoses in other states and localities,
only two have focused on determining naloxone availability through retail pharmacies in Georgia
(Nguyen et al., 2020; Stone et al., 2019). This study was done retrospectively of standing order
implementation. The study sample was limited to retail pharmacies with an active license as of
February 2020 and assessed availability during the summer of 2020. The study focused on
naloxone availability and did not ask or seek to describe pharmacists' attitudes and perceptions
and pharmacy staff related to naloxone dispensing.
Definition of Terms
The following terms are used throughout this research:
Naloxone. An opioid antagonist that reverses overdose symptoms by binding to opioid
receptors and reversing or blocking the effects of opioids (Substance Abuse and Mental
Health Services Administration, 2019).
Opioid overdose deaths. Deaths occurring because of overdoses from both prescription
and non-prescription (illicit) drugs.
Third-party prescription. Prescriptions issued to a family member, friend, or caregiver of
an individual at risk for opioid overdose (Prescription Drug Abuse Policy System, 2017).
Standing order. A law or administrative policy that allows prescribers to authorize
pharmacists to dispense a medication without an outside prescription. The standing order
serves as the prescription for the authorizing prescribers (Evoy et al., 2018).
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Naloxone Access Laws or Naloxone Laws: A broad set of laws that decrease civil and
criminal liabilities for laypersons, dispensers, and prescribers; and increase access to
naloxone via standing orders or 3rd party prescriptions (Prescription Drug Abuse Policy
System, 2017).
Retail pharmacy: A pharmacy open to the public that can fill prescriptions without any
requirements to seek medical care services from any pharmacy affiliates. In Georgia,
“retail pharmacy” means all pharmacies, except hospital, clinic, prison, and specialty
pharmacies, located in this state where a pharmacy is practiced (Ga. Comp. R. & Regs,
2003).
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CHAPTER 2
REVIEW OF SELECTED LITERATURE
This chapter presents the current literature around naloxone access policies with a focus
on standing orders. Attention will be given to three topics: the history of naloxone policies in
Georgia and nationally; national studies examining naloxone access laws; and state-specific
studies examining the naloxone access in pharmacies via standing orders. In addition, this
chapter will discuss health policy implications for this study. Lastly, a conceptual model is
presented to highlight the relationship of naloxone standing orders with respect to naloxone
availability, naloxone dispensing, and pharmacy and community-level factors based on the
current available literature.
History of U.S. and Georgia Naloxone Access Policies
Naloxone access policies are policies that are intended to increase access to naloxone.
The policies contain various provisions, including language that generally remove barriers and
increase access to naloxone (Davis, Chang, Carr, Hernandez-Delgado, & Breen, 2017). These
policies provide access to naloxone through non-patient specific mechanisms, such as standing
orders and third-party prescribing. They also provide immunity from civil and/or criminal
prosecution to prescribers, dispensers, and/or laypersons who administer naloxone to individuals
experiencing an opioid overdose. Naloxone access policies began to emerge in the early 2000s.
New Mexico was the first to pass legislation in 2001 to increase naloxone access (Rees et al.,
2017). Additional provisions under New Mexico’s legislation included removing civil and
criminal liability for layperson administration, prescribers, dispensers, and other administrators
("Overdose prevention/naloxone distribution," 2001). Connecticut followed soon after,
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implementing its naloxone access law in 2003 (Rees et al., 2017). As of 2017, all states have
some version of naloxone access policies in place.
As one specific type of naloxone access policy, standing orders improve access to
naloxone by removing the barrier of requiring a patient-specific prescription. Standing orders
provide blanket prescriptions for patients and consumers to eliminate the need for individual
prescriptions and provide easier access to certain drugs. Standing orders can be implemented in
organizations such as hospitals, or more widely, such as in pharmacies across entire states.
Nationally, standing orders for naloxone were not implemented in states until 2010, with Illinois
being the first state to implement such an order (Prescription Drug Abuse Policy System, 2017).
Figure 2.1 displays the increase in the prevalence of standing orders across the United States
from 2010 to 2017.
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Figure 2.1
Standing Orders Across the United States, 2010 – 2017

Note. Created using data from the Prescription Drug Abuse Policy System (PDAPS). Retrieved from
http://pdaps.org/datasets/laws-regulating-administration-of-naloxone-1501695139

In 2014, Governor Nathan Deal signed into law the Georgia 911 Medical Amnesty Law,
which provided legal protections for people who administer naloxone to some experiencing an
overdose (2014). The 2014 law allowed for naloxone prescriptions to be given to people who are
either at risk of overdose or persons who could assist someone who overdoses. However, a
person-specific prescription was still required as a provision of the law. Three years later, on
January 13, 2017, Dr. Brenda Fitzgerald, the Commissioner of Public Health, signed into effect
Georgia’s standing order for naloxone, allowing for access in a retail pharmacy without a
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patient-specific prescription (Georgia Department of Public Health, 2017). This standing order
provided access to four types of naloxone: two (2) intramuscular versions, administered
manually or automatically into the muscle with a needle, and two intranasal spray versions. On
April 18, 2017, Governor Nathan Deal signed into the law the Jeffrey Dallas Gay, Jr., Act
codifying expanded access to naloxone through the state’s standing order ("Jeffrey dallas gay, jr.
Act," 2017). The Act also removed civil and criminal liability to dispensers (i.e., pharmacists) in
the state. Access to naloxone through the standing order is a valuable policy strategy in the
toolbox of harm reduction strategies to address the opioid epidemic in Georgia.
Although standing orders have been a tool in place across the country for almost two
decades, access to the drug is not widespread and continues to vary. Previous research show
variations in whether pharmacies stock the drug (Evoy et al., 2018; Graves et al., 2019;
Meyerson et al., 2018). Additional barriers may be present such as cost and/or negative attitudes
of pharmacists toward dispensing. The cost of naloxone can be prohibitive (Zaller et al., 2013).
Negative attitudes often cause pharmacists not to fill requests under naloxone standing orders
(Meyerson et al., 2018; Puzantian & Gasper, 2018; Zaller et al., 2013). The next section of this
review explores studies exploring the naloxone access laws and opioid overdoses, individual
overdose education and naloxone access, state-specific studies, and Georgia specific studies.
Implications for health policy is also discussed, followed by a conceptual model, and expected
outcomes of this research.
National Studies Examining Naloxone Access Laws and Opioid Overdoses
Various studies have investigated the effects of naloxone access laws on opioid overdoses
and deaths, and the results of these studies have been mixed with respect to effectiveness.
McClellan et al. (2018) found that states with naloxone access laws, including standing orders,
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had a lower overdose mortality incidence. Among African-Americans, men, and adults aged 3544, naloxone access laws were associated with lower opioid overdose death incidence
(McClellan et al., 2018). Additional studies found that naloxone access laws were associated
with decreases in opioid overdose deaths (Doe-Simkins et al., 2009; Rees et al., 2017; Walley et
al., 2013).
Research showing no evidence or impact of naloxone laws is also present. There was no
evidence that naloxone access laws or good samaritan laws were associated with increases in
non-medical opioid use (McClellan et al., 2018). Research has shown that laws allowing
pharmacists to dispense naloxone without a prescription (direct authority) are associated with
reduced fatal opioid overdoses (Abouk et al., 2019). The same study found that naloxone access
laws increased emergency department visits for overdoses (Abouk et al., 2019). Doleac and
Mukherjee (2018) presented evidence that naloxone access laws had no effect on opioid
overdose fatalities in urban areas but increased opioid-related crime and emergency room visits.
Individual Overdose Education and Naloxone Access
Community-based overdose education and naloxone distribution programs, also referred
to as OEND programs, provide education, training, and naloxone to at-risk individuals or others
that have access to at-risk people (such as friends, family members, or other caregivers). Many of
these programs have been implemented over the past two decades. Wheeler and colleagues
described at least 188 community-based programs in 2010 (Wheeler et al., 2012). To date, takehome naloxone programs have been established in approximately 200 communities throughout
the United States (Harm Reduction Coalition, n.d.). From 1996 to June 2010, 48 known OEND
programs in 15 states and the District of Columbia provided training and distributed naloxone to
approximately 53,000 people and reversed approximately 10,000 overdose reversals using
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naloxone (Wheeler et al., 2012). Communities with naloxone access programs also saw
decreases in overdose mortality after implementation (Giglio et al., 2015; McDonald & Strang,
2016), sometimes with naloxone administered with little to no training (Doe-Simkins et al.,
2009; Walley et al., 2013) Studies have also shown that injection drug users can be trained to
respond to overdose events and successfully use naloxone to reverse potentially fatal overdose
events (Doe-Simkins et al., 2009; Seal et al., 2005). Research has shown these programs to be
effective, but determining intended population impacts are difficult, as many programs focus on
the amount of people trained (Haegerich et al., 2014).
For Georgians, there are limited OEND programs available in the state. The Atlanta
Harm Reduction Coalition provides free Narcan to community members across Georgia, with
efforts focused in the city of Atlanta (Atlanta Harm Reduction Coalition, 2020). The Georgia
Overdose Prevention Program also provides access to naloxone, in partnership with the Atlanta
Harm Reduction Coalition, but requires a prescription to obtain it (Georgia Overdose Prevention,
2020). Nationally, Emergent BioSolutions, the company that makes Narcan, offers naloxone
free of charge (D’Angelo, 2018). Next Naloxone, an online and mail-based opioid overdose
response training platform that facilitates access to naloxone through the mail, does not have
affiliates in Georgia but does offer expired nasal spray and mail-to-order intramuscular naloxone
(sent after requester views a training video) (NEXT Naloxone, 2020). Previous research has
shown that expired naloxone can retain most of its potency for many years past expiration (Pruyn
et al., 2019). Data on naloxone distribution and overdose reversals are not publicly available
from any of these programs. Community access across the state is limited, meaning that
pharmacy access to naloxone is critical, especially in rural portions of Georgia.
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State-Specific Studies on Naloxone Access via Standing Orders in Community Pharmacies
More recently, there has been an increase in literature available describing the impact of
providing access to naloxone via standing orders. This research provides insight into both the
effect of naloxone access laws and the association between them and opioid overdoses and
deaths. To date, studies have been published that examine naloxone access under standing
orders in Indiana, Texas, California, New Jersey, Pennsylvania, Alabama, North Carolina, New
York, and Georgia. These studies provide context regarding naloxone availability and potential
barriers to access understanding orders, and they inform current research in other communities
and states.
In Indiana, Meyerson et al. (2018) conducted an online survey of managing pharmacists
in community pharmacies. They found that 73% of pharmacists believed a newly enacted state
standing order for naloxone would increase the likelihood of their pharmacy stocking. Only 67%
believed that the standing order would increase the likelihood that they or their staff would
dispense naloxone. This study also found that chain pharmacies, pharmacies with more than one
full-time licensed pharmacist, and pharmacies where the managing pharmacist had received
continuing education on naloxone within the past two years were more likely to stock naloxone.
Over half (58.1%) of pharmacies stocked naloxone. Interestingly, researchers note that while the
state standing order may have facilitated stocking, regression analysis results showed that one or
more factors shared by larger and more systematized pharmacies (such as being a chain
pharmacy, having more than one full-time pharmacist, and continuing naloxone education for the
managing pharmacist within the past two years), was important in determining who stocked it.
No significant variables predicted whether a pharmacist would dispense.
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In Texas, research by Evoy et al. found about 69% of pharmacies from four major
pharmacy chains stocked naloxone and would dispense it 32 months after standing order
implementation (2018). Eighty-four percent indicated they would dispense naloxone without a
prescription. About half of pharmacies would bill insurance for naloxone dispensed under the
standing order. This study did not include independent pharmacies or other retail pharmacies
outside of the four major chains since there was no statewide standing order in place. Even with
the standing order, access barriers to include pharmacists' understanding of the order remained
(as some pharmacists stated that the standing order only applied during acute overdoses).
California researchers looked at naloxone availability two years following the state’s
standing order implementation (Puzantian & Gasper, 2018). Approximately 24% of retail
pharmacies furnished naloxone to patients without a physician's prescription. Reasons for the
low percentage of pharmacies practicing under the standing order included lack of knowledge
regarding legislation, lack of required training, stigma about substance use disorder, and time.
Regarding cost, about 60% of pharmacists knew that naloxone could be billed to insurance plans.
The median cash prices of nasal naloxone (which is used most often by community members) at
chain pharmacies was $136 versus $150 at independent pharmacies. There were no statistically
significant differences in urban-rural classification availability, which may be the case as this
study had low rural pharmacy representation. This study was limited by low rural pharmacy
representation and lack of information on why pharmacists would not supply naloxone.
In New Jersey, a 2019 survey of retail pharmacies in 10 cities compared naloxone
availability to median household income, population, and the prevalence of opioid-related
hospital visits (Lozo et al., 2019). Results showed that 31% of pharmacies had naloxone
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available. Increases in household median income were associated with increased pharmacy
availability. More populous areas were associated with less pharmacy naloxone availability.
Graves et al. (2019) conducted a telephone survey of Pennsylvania pharmacies across the
state to assess the availability and price of naloxone, and pharmacy staff knowledge of the state’s
standing order for naloxone. Researchers found that naloxone was stocked in 45% of pharmacies
and could be ordered for pickup in one business day in the pharmacies that did not have
naloxone in stock (55%). Most pharmacy staff answered all questions correctly pertaining to
understanding of the naloxone standing order. Prices for naloxone varied by formulation, with a
range from $50 to $4,000. National pharmacy chain staff were more likely than regional/local
chain and non-chain pharmacy staff to acknowledge that a prescription was not required to get
naloxone. In Philadelphia, researchers saw significant differences in the availability of naloxone
by pharmacy type and neighborhood characteristics (Guadamuz et al., 2019). About 32% of
pharmacies had naloxone nasal spray in stock, and about 62% noted that it could be obtained
without a prescription. Naloxone was both more likely to be in stock and available without a
prescription in chain stores than in independent stores. The median cost of naloxone without
insurance was $145 (Guadamuz et al., 2019).
In Alabama, pharmacies in two Birmingham counties were surveyed to assess the
availability of various formulations of naloxone at chain and independent pharmacies in rural
and urban areas, in addition to gathering information about pharmacists’ attitudes toward
naloxone and potential barriers of pharmacy naloxone distribution (Sisson et al., 2019).
Independent pharmacies were less likely to have naloxone in stock, and rural pharmacies needed
more time to obtain naloxone and offered less extensive training on naloxone use. There were no
differences in dispensing based on rurality. Interestingly, over 80% of pharmacists expressed at
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least one negative belief about naloxone, such as believing that naloxone promotes riskier opioid
use. Although cost information was not gathered, pharmacists shared that costs to patients and
the pharmacy were contributing factors for not dispensing more naloxone kits. There were no
significant differences in dispensing between urban and rural pharmacies. However, significant
differences in stocking were present, with chain pharmacies and urban pharmacies more likely to
stock naloxone than independent and rural pharmacies (Sisson et al., 2019).
A statewide survey of North Carolina pharmacies sought to gather additional information
around naloxone standing order implementation and community characteristics associated with
stocking and dispensing under North Carolina’s standing order (Egan, Foster, Knudsen, & Lee,
2020b). Researchers also gathered information about out-of-pocket costs for intranasal naloxone.
The study found that about 62% of pharmacies have naloxone available without a prescription.
The odds of availability were lower in independent pharmacies than chain pharmacies. Lastly,
naloxone availability was lower in communities with higher percentages of residents with public
health insurance. This study also reviewed correlates of naloxone availability and out-of-pocket
costs. The only neighborhood characteristic significantly associated with naloxone availability
was the percentage of residents with public health insurance, with lower availability in
communities with higher percentages of residents with public health insurance. No correlates for
out-of-pocket costs were significant.
In New York City, the New York Times wrote an investigative report of naloxone
availability in pharmacies included in the city’s NYC Naloxone Standing Order Initiative
(Correal, 2018), which provided city-wide access to anyone who requested naloxone under the
city’s standing order. This investigation found that about a third of pharmacies (270) on the list
had naloxone in stock and would dispense it without a prescription. However, 360 pharmacies on
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the list did not have naloxone available, and in feedback gathered from contacting pharmacies,
most pharmacists said it was out of stock, there was low demand, and that it could be ordered.
There was also confusion about the need for a prescription, although the pharmacies contacted
were noted as participating in the city’s standing order.
Across studies, variability with naloxone dispensing, stocking, and pharmacists’ and
pharmacy staff knowledge, attitudes, and beliefs related to naloxone dispensing have played a
critical role in public access for naloxone in various ways. Although these studies provide insight
into the role of facilitators and barriers to naloxone access, it also highlights the challenges faced
when implementing policy approaches to fight this epidemic. Knowledge, attitude, and belief
barriers to dispensing persist, including legality perceptions, practice/policy, and stigmatizing
attitudes (Hammett et al., 2014; Zaller et al., 2013). Pharmacists’ knowledge, attitudes, and
beliefs can increase naloxone stocking and dispensing (Meyerson et al., 2018; Sisson et al.,
2019) or prevent access to someone under standing orders (Bailey & Wermeling, 2014;
Puzantian & Gasper, 2018; Raisch et al., 2005), even when it is most desired by people who
inject drugs (Hammett et al., 2014). Even after standing order implementation, many may
(Graves et al., 2019; Guadamuz et al., 2019) or may not be (Correal, 2018; Evoy et al., 2018)
aware of the naloxone availability under standing orders. On the other hand, research has shown
that no significant variables predicted whether a pharmacist would dispense (Meyerson et al.,
2018). In several of these studies, retail/chain pharmacies were found to be more likely to stock
and dispense than independent/local pharmacies (Egan et al., 2020; Graves et al., 2019;
Guadamuz et al., 2019; Meyerson et al., 2018; Sisson et al., 2019). About one-third to less than
half of pharmacies had naloxone in stock (Graves et al., 2019; Lozo et al., 2019). Concerning
dispensing, one study found no differences in dispensing based on rurality (Sisson et al., 2019),
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while others reported a low number dispensed to patients with no prescription (Puzantian &
Gasper, 2018). No differences in naloxone availability by urban-rural classification were shown
(Puzantian & Gasper, 2018). Costs and whether insurance covers the different formulations of
naloxone available under standing orders have varied and are also shown to be a barrier
(Bakhireva et al., 2018; Davis & Carr 2015; Sisson et al., 2019; Zaller et al., 2013). Naloxone is
more expensive in independent versus chain pharmacies (Puzantian & Gasper, 2018), with at
least half willing to bill to insurance for naloxone dispensed under standing orders (Evoy et al.,
2018; Puzantian & Gasper, 2018). When it comes to household income and public health
insurance, increased percentages of residents with public health insurance (Sisson et al., 2019),
and increased household incomes (Lozo et al., 2019) were associated with increased pharmacy
availability. Other research has shown that naloxone availability was lower in communities with
higher percentages of residents with public health insurance (Egan, Foster, Knudsen, & Lee,
2020b).
There is variation in access to naloxone years after standing orders are implemented, with
slow adoption of orders in some areas and no consistent trends in availability after standing order
implementation in other areas. These studies provide insight into the possibilities present
regarding the landscape of naloxone availability in Georgia and what may be occurring across
the state.
Georgia-Specific Studies
To date, two studies have been published investigating naloxone access under Georgia’s
standing order (Nguyen et al., 2020; Stone et al., 2019). Stone, Hur, and Young found that less
than six months after the standing order was implemented, most community pharmacies across
the state (69%) did not have naloxone stocked (2019). It was less likely to be available in
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independent pharmacies and less like to be available in areas with lower mortality rates.
Research by Nguyen et al. (2020) focused on rural Georgia, finding that although the legal
barrier to naloxone availability had been removed for approximately four years, only about half
(54.7%) of pharmacies had the medication in stock, and the average cost of the drug is $131.04.
Pharmacists in less than half of the stores contacted (47.1%) noted that a prescription was not
necessary. Previous research indicates that rural areas may not see the benefits of state-level
policies such as standing orders because of the few geographically or financially accessible
pharmacies that would stock naloxone (Masterman, 2019).
Policies to combat public health issues provide a way for addressing issues widely. Laws
increasing layperson engagement in opioid-overdose reversal were associated with reduced
opioid-overdose mortality (McClellan et al., 2018). Although availability is not consistent,
naloxone distribution shows promise in preventing overdoses in communities. Before 2018,
limited literature has been published to assess pharmacy access and practice (Björnsdottir et al.,
2020). Determining the availability of naloxone under the state’s standing order provides
essential data and information to assess the potential impacts as intended by law. Additional
research is needed to further investigate pharmacy availability in the entire state of Georgia, as
well as describe associations between availability, community characteristics, and overdose
deaths in communities across the state.
Political Preferences and the Opioid Epidemic
While it is important to consider current health and community-related socioeconomic
factors that influence naloxone policy success, it is also important to note the possible political
influences of opioid overdose prevention policies and the successful implementation of those
policies. The public health response to the current opioid epidemic contrasts with the law
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enforcement response to the opioid epidemics of the 1960s/1970s and the 1980s/1990s (James &
Jordan, 2018). The differences in these responses are mainly due to the populations affected,
with the earlier opioid epidemic affecting black persons and low income, rural white persons
(Cuéllar & Humphreys, 2019). The current epidemic largely affects middle-class white persons
with more political and social capital (Cuéllar & Humphreys, 2019). Data from 2018 show that
nationally, age-adjusted death rates for white persons were 18.6 compared to 14.0 for black
persons (Wilson et al., 2020). In Georgia, these rates were 11.6 for white persons compared to
3.7 for black persons (Georgia Department of Public Health, 2020a; Wilson et al., 2020). The
differences in responses to the opioid epidemic could also be attributed to the severity of the
epidemic wearing down historic resistance to public-health driven drug policy, mainly by
persons identifying as Republican (Cuéllar & Humphreys, 2019). Generally speaking, Democrats
tend to lead more liberal policies, and Republicans more conservative policies (Caughey et al.,
2017). Public health effects of opioid-related policies have been studied, but limited research is
available to describe the political effects and outcomes related to opioid policy implementation.
Kaufman and Hersh (2020) highlight research that considers the politically mobilizing outcomes
of other traumatic events like terrorism, race riots, and war, noting the politically mobilizing
effects of these types of events. When reviewing the literature on partisan preferences, results are
mixed. On average, victims of terrorism become more conservative (Hersh, 2013), while those
close to race riots become more liberal (Enos et al., 2019). Republicans are less supportive of
treatment policies than Democrats overall (De Benedictis-Kessner & Hankinson, 2019), and
anxiety can lead to more liberal preferences, while fear may lead to conservative preferences
(Kaufman & Hersh, 2020). Additional research has shown that legislators that are female,
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Democrat, and liberal were more likely to support comprehensive opioid use disorder laws
(Nelson & Purtle, 2020).
Based on this previous research, there is reason to investigate the relationship between
political preferences and policy outcomes. Political preferences may drive local and national
policy outcomes (Kaufman & Hersh, 2020) and affect how successful implementation of a
voluntary policy is within a particular community.
Literature Summary
Across all studies, various themes emerge from the research on naloxone access laws and
naloxone availability. Impacts of naloxone access laws have been mixed. Some studies have
shown that states with naloxone access laws and direct dispensing are associated with lower
overdose mortality incidence (Abouk et al., 2019; Doe-Simkins et al., 2009; McClellan et al.,
2018; Rees et al., 2017; Walley et al., 2013). Others show increased opioid overdoses in states
with naloxone access laws (Abouk et al., 2019; Doleac & Mukherjee, 2018). Additional research
results show no evidence or association between opioid overdose increases and naloxone access
laws (McClellan et al., 2018) and specifically, no effect in urban areas (Doleac & Mukherjee,
2018). State-specific studies have also shown variation in access to naloxone years after standing
order implementation, slow adoption of standing orders in some areas, and no consistent trends
in availability after standing order implementation. Additionally, considering political influences
on the adoption of opioid-related policies is important. Research in this area is currently limited
with mixed results. There is reason to investigate whether a national epidemic of this proportion
would also be impacted by politics and political preferences, especially with a voluntary state
standing order.
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Policy Implementation Approaches and the Policy Implementation Framework
Policy implementation can be described as the “carrying out of a basic policy decision
usually incorporated in a statute but which can also take the form of important executive orders
or court decisions” (Mazmanian & Sabatier, 1983). A policy decision “identifies the problem(s)
to be addressed, stipulates the objective(s) to be pursued, and structures the implementation
process” (Sabatier & Mazmanian, 1980). Policy implementation approaches are often classified
as top-down, bottom-up, or a combination of these two approaches. Each approach is appropriate
for certain types of policies, with pros and cons for each.
The top-down approach to policy implementation posits that policies are created by
central actors or at central levels, then implemented by actors at lower levels (Matland, 1995).
Top-down approaches begin with a clear policy statement of the policy-makers’ intent, then
continue with language that has more specific steps to define what is expected to be implemented
(Paudel, 2009). Those who use this approach usually focus on a specific political decision or law
and follow the implementation of that decision, focusing on measuring outcomes in terms of the
policy’s original intent (Paudel, 2009). Policies that use top-down implementation approaches
include those that have a strong political direction and are more likely in areas of high conflict
about the goal but relatively high certainty on how it the policy solution could be created and
implemented (e.g., taxation for a specific industry sector) (Matland, 1995). Translating this to
Georgia’s standing order, analysis of this order would begin with the standing order, using the
structure and statutory language to evaluate outputs and impacts of its implementation.
The bottom-up approach to policy implementation posits that policy is made at the local
level, and implementation starts with those charged with implementation taking the lead to
determine how policy is implemented and what measures are appropriate to demonstrate
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successful outcomes (Matland, 1995). The bottom-up approach identifies the networks of actors
involved in service delivery in one or more local areas and asks them about their goals,
strategies, activities, and contacts (Matland, 1995). It then uses that network to inform the
planning and execution of the policy, which places the power of determining how policy is
implemented with those that are implementing. In terms of policy areas, the bottom-up approach
is used to examine policies that address issues with greater uncertainty, complex policies, and
policies that lend themselves to descriptive rather than prescriptive approaches (ex. addressing
educational disadvantages) (Matland, 1995). Translating this to Georgia’s standing order, the
analysis would begin with pharmacists, as the implementers, in determining how to offer
naloxone in pharmacies.
A combination of the top-down and bottom-up approaches can also be used as an
approach to policy implementation. Combining the two approaches combines the strengths of
both approaches and offers a way to engage policymakers at not only the top but also those that
are important to successful implementation. Policy implementation can be a complex process
that involves a wide range of stakeholders that interact at all levels of policy implementation
(both those that have the power to enforce decisions and those that are important to
implementation efforts). Using this approach in relation to Georgia’s standing order,
pharmacists would be consulted on ways to offer naloxone in pharmacies, and state policymakers would work collaboratively with pharmacists in the state to determine if a standing order
is the best course of action, and if so, what that order should include.
The definition of successful implementation is also important to consider when
discussing policy implementation. Using a top-down approach, successful implementation is
measured by the outcomes resulting directly from policy implementation (Matland, 1995). For
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example, the successful implementation of a tax policy could focus on the amount of taxes
collected. Using the bottom-up approach, successful implementation concentrates not on the
policy's direct results, but the policy implementers' motives and actions (Schofield, 2001).
In reviewing the policy implementation approaches, the most appropriate approach for
Georgia’s standing order is the top-down approach. This standing order lends itself to the topdown approach to policy implementation because it is simple policy solutions, the
implementation of which should provide a tool to decrease opioid overdose mortality. Successful
implementation of standing orders should provide access to naloxone without requiring a
prescription by pharmacists. Analysis of this standing order should be taken with this approach
in mind. Although this research focuses on outputs of a specific policy, it is important to
consider that the policy implementation process can and does determine the success of policy
outcomes.
Creating policies or statutes does not guarantee success on the ground if policies are not
implemented well. It is also important to understand the variables and contextual factors that
affect implementation. A comprehensive policy implementation framework created by Sabatier
and Mazmanian uses the top-down approach to policy implementation to provide a guide that
identifies variables affecting policy implementation, variables illustrating achievement of policy
goals, and variables explaining the effects of socioeconomic conditions, public opinion, and
other factors on the implementation process (1980). There are three broad categories of
independent variables that influence the policy implementation process: (1) the tractability of the
problem being addressed by the statute; (2) the ability of the statute to favorably structure the
implementation process; and (3) the net effect of a variety of "political" variables on the balance
of support for statutory objectives (Sabatier & Mazmanian, 1980). The stages in the
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implementation process are also vital in assessing policy implementation. Each stage of policy
implementation can be viewed as an endpoint or dependent variable but are also successive, with
earlier stages impacting later stages. The framework divides the implementation process into
five different stages, with each subsequent stage representing a dependent variable that is
influenced by the one before. Figure 2.2 provides a visual depiction of the framework.
Tractability of the Problem
This group of variables describes the degree to which the problem to be addressed by the
intended policy solution can be solved. Variables that inform the tractability of the problem
include technical difficulties, diversity of target group behavior, target group as a percentage of
the population, and the extent of behavior change required.
Ability of Statue to Structure Implementation
The language and legal objectives included in the policy or statute are vital to
implementation. That language allows policymakers to use available levers to ensure successful
implementation and attainment of policy objectives. These levers include determining
implementing organizations, providing legal and financial resources to implementing
organizations, In determine implementing institutions, legal and financial resources to
implementing institutions, hierarchical integration of with implementing institutions, decision
rules of implementing institutions, recruitment of implementing agency officials, and formal
access by outside actors or affected citizens to participate as formal intervenors in agency
proceedings or petitions to the policy and parts of the implementation process.
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Non-Statutory Variables Affecting Implementation
This group of variables account for the impacts of non-statutory variables that do not
relate to the legal structure of implementation but affect how policies are implemented.
Collectively, they describe contextual impacts that affect how policies are implemented. As
Mazmanian and Sabatier explain, these include primary external variables affecting policy
outputs for implementing agencies, which determines whether policy objectives are met
(Sabatier & Mazmanian, 1980).
Stages (Dependent Variables) of the Implementation Process.
Within the Policy Implementation Framework, the process of implementing policies
represent various endpoints important to successful implementation. These include 1) policy
outputs of the implementing agency; 2) compliance of target groups; 3) actual impact of agency
decisions; 4) perceived impacts of agency decisions; and 5) major revisions in the statute.
Analysis of policy implementation can focus on one endpoint (stage) or the entire process while
accounting for independent variables listed based on the framework.
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Figure 2.2
Policy Implementation Framework

Note. Adapted from Sabatier, P., & Mazmanian, D. (1980). The Implementation of Public Policy: A Framework of
Analysis. 8(4), 538-560. doi:10.1111/j.1541-0072.1980.tb01266.x

Applying the Policy Implementation Framework
Applicability of the policy implementation framework can provide insight into variables
relevant to naloxone availability via standing orders for retail pharmacies. Based on the standing
orders’ intent (Georgia Department of Public Health, 2017), applying the top-down approach to
policy implementation, and using the Policy Implementation Framework, a conceptual model for
implementing Georgia’s standing order is provided in Figure 2.3. This model provides a visual
depiction of select independent factors affecting implementation and the dependent factor of the
policy implementation process that is the focus of this study.

41
A top-down policy that addresses tractability, non-statutory, and statutory independent
variables influences a particular policy's implementation process. If implementation is structured
successfully, the policy output (standing order) will lead to compliance (naloxone availability),
and actual impacts (Increased naloxone dispensing) will be shown.
Tractability of the Problem
A proxy for this group of variables is opioid overdose death rates, which provide context
to the public health burden and need for naloxone in a community. Using opioid overdose death
rates as a marker for need has been done in previous studies (Meyerson et al., 2018; Stopka et al.,
2017).
Ability of Statute to Structure Implementation
Standing order language is important to consider in implementation. As mentioned,
Georgia’s standing order lends itself to the top-down approach to policy implementation because
it is a simple policy solution. The purpose of the order is clearly stated, which is to facilitate the
availability of naloxone “to family members, friends, co-workers, and other persons (eligible
persons) that can provide assistance to those experiencing opioid-related overdose” (Georgia
Department of Public Health, 2017). The implementation of the policy is simple, only requiring
that pharmacies use the standing order as a prescription for eligible persons. Lastly, a listing of
types of naloxone available for use under the standing order is included as a reference for
implementing pharmacies.
Non-Statutory Variables Affecting Implementation
Many non-statutory variables could affect the implementation of the statewide standing
order. Select socio-economic conditions are explored in this study. They include county-level
median household income, county urbanicity and rurality as noted by USDA Rural-Urban
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Continuum Codes (RUCCs), and cost of naloxone. Also included in this group of categories are
pharmacy type and county political leaning. Pharmacists' knowledge of the standing order could
also affect successful implementation. Based on this research, a proxy for that would be the
percentage of pharmacy staff affirming access to naloxone without a prescription.
Compliance Stage of the Implementation Process
This research focuses on the compliance with policy outputs by target groups in its
design. Other variables and other stages are important to consider but are beyond the scope of
this study.
As with most public policy efforts, a model to inform policy had not been created prepolicy and using available information, a post-policy model is included above. While this model
simplifies the relationship between Georgia’s standing order and intended outcomes, it is
important to note that other considerations beyond the scope of this research should be
considered as more researchers investigate the effects of this policy solution on the opioid
epidemic. Factors that may affect community access to naloxone include stocking and dispensing
of naloxone, pharmacists’ availability in rural areas, cost of naloxone, and pharmacists’ attitudes
toward dispensing naloxone. Compared to primary care physicians, access to pharmacists in rural
areas is greater because pharmacists are more widely distributed geographically than primary
care physicians (Casey et al., 2002). This could mean that people are more likely to have better
access to a pharmacist than a primary care doctor, as people tend to have less access
geographically and financially to primary health care (Masterman, 2019). Pharmacies provide an
avenue to get naloxone outside of OEND programs, as OEND programs are not widely available
in rural areas (Kerensky & Walley, 2017). The cost of naloxone is also a challenge that can
affect actual policy impacts. Prices for the same prescription drug can differ across pharmacies in
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the same town (Sorensen, 2000). Casey, Klingner, and Moscovice Casey et al. (2002) found that
financial access to pharmacy services (paying for prescriptions) for rural consumers is a serious
concern, especially for the rural elderly who lack prescription drug coverage (2002). For
naloxone, many insurance plans may cover naloxone, but that can vary by state. The cost of the
types of naloxone available to the public varies as well. Amphastar, which makes 1-mg-permilliliter injections, the dose used off-label as a nasal spray, was priced at $39.60 in 2016 (Gupta
et al., 2016). Newer, easier-to-use formulations are even more expensive. Narcan costs $150 for
two nasal-spray doses (Gupta et al., 2016). A two-dose Evzio package was priced at $690 in
2014 but is now $4,500, a price increase of more than 500% in just over two years (Gupta et al.,
2016). Even if one has the physical and financial means to access naloxone in a pharmacy,
pharmacists’ attitudes to dispensing naloxone also present a barrier.
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Figure 2.3
Conceptual Model Based on the Policy Implementation Framework

Note. Independent variables and dependent variables included in this study are noted in red.

Derivation of Hypotheses
Based on the top-down approach to policy implementation, the conceptual model
presented in this chapter, and previous research, hypotheses for each study aim are listed below.
Research Aim 1: Describe and Explore Naloxone Availability in Retail Pharmacies across
Urban and Rural Georgia.
•

Research Question 1 (Availability): What is the availability of naloxone in retail
pharmacies 44 months after implementation of Georgia’s naloxone standing order, which
allows pharmacies to dispense naloxone without a person-specific prescription?
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o Hypothesis 1: There will be a reported increase in naloxone availability
compared to previous research in Georgia. In terms of naloxone availability in
retail pharmacies, this simple, straightforward policy implemented using a topdown approach will mean that pharmacies will abide by it and dispense naloxone
under the standing order when requested.
Research Aim 2: Examine Pharmacy and Community-Level Factors Identified in the
Literature for Association with Naloxone Availability and For Usefulness in Predicting
Availability.
•

Research Question 2 (Associations with Availability): What pharmacy and
community-level factors are associated with naloxone availability in retail pharmacies 44
months after the implementation of Georgia’s naloxone standing order?
o Hypothesis 2: Naloxone availability is associated with pharmacy type.
o Hypothesis 3: Naloxone availability is associated with county rurality/urbanicity.
o Hypothesis 4: Naloxone availability is associated with high overdose death rates.
o Hypothesis 5: Naloxone is associated with county median household income.
o Hypothesis 6: Naloxone availability is associated with county political
preferences (political leaning).

•

Research Question 3 (Predicting Availability): Can naloxone availability be predicted
based on rurality/urbanicity, and other pharmacy and community-level factors, such as
retail pharmacy type, household income, opioid overdose deaths, and political leaning?

•

Hypothesis 7: Naloxone availability can be predicted based on retail pharmacy type,
rurality/urbanicity, opioid overdose deaths, median household income, and political
leaning.
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CHAPTER 3
METHODOLOGY
Overview
This cross-sectional policy implementation study investigated the availability of naloxone in
retail pharmacies across Georgia 44 months after the implementation of a statewide naloxone
standing order. To assess naloxone availability across the state, primary data was collected from
retail pharmacies with active licenses as of February 2020. Descriptive analyses were performed
to characterize survey results as well as select pharmacy and community-level factors. Chisquare tests were conducted to assess associations between naloxone availability and select
pharmacy and community-level factors. Finally, a multiple logistic regression analysis was
conducted to test a model that predicts naloxone availability based on select pharmacy and
community-level factors identified in the literature.
Purpose and Significance of the Study
The purpose of this study is to investigate the availability of naloxone 44 months after the
implementation of Georgia’s naloxone standing order. Standing orders are provided as a vehicle
to authorize, but not require, pharmacists to dispense medications without a patient-specific
prescription. Standing orders have been implemented in various states to remove barriers and
improve naloxone access for opioid overdose reversals. Previous research has shown that even in
states with standing orders for naloxone, availability continues to be an issue (Correal, 2018;
Evoy et al., 2018; Graves et al., 2019; Guadamuz et al., 2019; Meyerson et al., 2018; Puzantian
& Gasper, 2018). Since naloxone availability has been identified as an important activity in
responding to the opioid epidemic (U.S. Department of Health and Human Services, 2015), it is
important to conduct research to describe the availability of this opioid antagonist in Georgia.
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Two research studies have been published to describe naloxone availability shortly after standing
order implementation, and through retail community pharmacies in rural areas of the state. The
first Georgia study was conducted in 2017, approximately four months after implementation of
the statewide naloxone standing order and immediately after the singing of Georgia House bill
249 codifying the standing order into state law. This study showed that about one-third (31%) of
pharmacies had naloxone in stock, with most pharmacies (69%) not stocking naloxone (Stone et
al., 2019). Chain pharmacies and areas with high opioid mortality rates were more likely to have
naloxone available for same-day purchase (Stone et al., 2019). Stone et al. (2019) did not assess
prescription needs or costs for naloxone. The second Georgia study was conducted 28 months
after standing order implementation and focused specifically on rural Georgia pharmacies. This
study showed that a little more than half (54.7%) of pharmacies surveyed had naloxone in stock,
and less than half (47.1%) were willing to provide it without a prescription (Nguyen et al., 2020).
The mean cash price was $131.04. Additional research is needed to determine if availability has
improved and to describe naloxone availability in both urban and rural areas of the state.
Conceptual Framework
Based on the standing orders’ intent (Georgia Department of Public Health, 2017),
applying the top-down approach to policy implementation, and using the policy implementation
framework (Sabatier & Mazmanian, 1980), a conceptual logic model for naloxone access is
provided in Figure 2.3. The model provides a visual depiction of the study-specific independent
and dependent variables that could impact standing order implementation. Study-specific
independent variables include knowledge of standing order, pharmacy type, county political
leaning, county-level median household income, county urbanicity and rurality, and cost of
naloxone. The “compliance” implementation phase, represented by naloxone availability, is the
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dependent variable and the focus of this research. As stated in Chapter 2, a top-down policy that
addresses tractability, non-statutory, and statutory independent variables influences the
implementation process for a particular policy. If implementation is structured successfully, the
policy output (standing order) will lead to compliance (naloxone availability), and actual impacts
(Increased naloxone dispensing) will be shown.
Research Questions
This research sought to answer three research questions. Research questions are noted
below. Details on the research design for this study are described in the following sections, with
references made to which research question is addressed.
•

Research Question 1 (Availability): What is the availability of naloxone in retail
pharmacies 44 months after the implementation of Georgia’s naloxone standing order?

•

Research Question 2 (Associations with Availability): What pharmacy and
community-level factors are associated with naloxone availability in retail pharmacies 44
months after the implementation of Georgia’s naloxone standing order?

•

Research Question 3 (Predicting Availability): How well can naloxone availability be
predicted based on pharmacy and community-level factors, to include rurality and
urbanicity, retail pharmacy type, county median household income, county age-adjusted
opioid overdose death rates, and county political leaning?

Research Approach and Methods
This study used a naturalistic inquiry approach to gather primary data on naloxone
availability across the state. This data was used to answer three research questions. Chi-square
analyses were conducted to determine associations between naloxone availability and pharmacy
and community – level factors for Research Question 2. For Research Question 3, a multiple
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logistic regression model was used to predict naloxone availability based on urbanicity/rurality
and other pharmacy and community – level factors. Prior to conducting all statistical tests and
analyses, data were tested to ensure that assumptions for statistical tests were met. For primary
data collection, a simulated client methodology was used to collect data from retail pharmacies
in Georgia with active licenses as of February 2020 via an anonymous telephone survey. This
simulated client approach has been used in previous research and is helpful in determining access
to healthcare services, appointment availability studies, and discrepancies in access to care
(Draeger et al., 2014; Hsiang et al., 2019; King et al., 2019; Pollack et al., 2016; Wiznia et al.,
2017). Simulated client studies have also been used in pharmacies to enhance pharmacists’
counseling skills (Xu et al., 2012). This method has also been used to describe pharmacy
communication (Wilkinson et al., 2012) and emergency contraception access for adolescents
(Uysal et al., 2019). The use of this methodology has become more frequent in investigating
pharmacy practice. Until recently, only five studies had been published in the U.S. between 2006
and 2016 that used a simulated patient approach to describe drug access and counseling
behaviors in community pharmacies (Bell et al., 2014; Deibert et al., 2006; French & Kaunitz,
2007; Jordan et al., 2011; Kavalieratos et al., 2010). A recent systematic review conducted by
Björnsdottir et al. (2020) found 148 studies that used a simulated patient protocol to conduct
pharmacy practice research worldwide during this same time period (2006 – 2016). There is
value in using a simulated patient approach in this study because it: 1) offers the opportunity to
observe naturally occurring public behavior; 2) addresses potential Hawthorne Effect biases and
increases scientific validity by decreasing the chance respondents will report socially desirable
results; and 3) limits risks to respondents as they are contacted via brief phone interactions about
pharmacy access for a specific drug, and person-specific information is not gathered.
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Research Design
For Research Question 1 (naloxone availability), an observational survey was employed
using a simulated client approach to gather cross-sectional data on naloxone availability. Seven
data collectors surveyed pharmacies during August 2020. Data was collected via a Google form
to ensure ease of reporting access for interviewers. Data from the form was populated into a
master spreadsheet for analysis using SPSS version 27. Responses allowed for free text in some
areas and required “yes” or “no” response or selection of a predefined categorical response in
other areas. To assist with data analysis, answers to the survey questions were transformed into
categories as appropriate. Free text fields were included to document contextual comments
about encounters, including how calls were handled by pharmacy staff and additional
information provided by staff that did not fit in predetermined categories. For all free text fields,
the primary researcher reviewed responses to determine categories for statistical analysis. Survey
questions from three previous studies were used to develop the survey to investigate naloxone
availability (Puzantian & Gasper, 2018) (Evoy et al., 2018) (Guadamuz et al., 2019). Price
information was also collected to determine price variability across the state. To answer
Research Question 2 (associations with availability), a chi-square analysis for each variable was
conducted to determine whether county-level variables were associated with naloxone
availability. This analysis was conducted to provide the most appropriate measure of association
with the data. To answer Research Question 3 (predicting availability), a multiple logistic
regression analysis was performed. This regression analysis predicted naloxone availability, a
binary dependent variable measured on a dichotomous scale – “in stock or could order” or “out
of stock and did not sell” on the day of inquiry, based on county rurality (independent variable
based on RUCC groupings) and other community markers of naloxone need, to include age-
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adjusted county opioid overdose deaths (independent variable), county median household
income (independent variable using American Community Survey data), pharmacy type
(independent variable noted as a chain or independent pharmacy, based on the number of
locations in the state), and political leaning (independent variable based on 2016 election results
by county).
Data Sources
Dependent Variable
•

Naloxone availability was determined by collecting primary data via a telephone survey
using a simulated client approach. A listing of licensed pharmacies obtained from the
Georgia Board of Pharmacy Roster in February 2020. The pharmacy roster is an Excel
file that includes the following information: name, license number, address, city, state,
zip, county, issue date, and expiration date. Rosters are updated at the beginning of every
month. Naloxone availability is noted as “available” for pharmacies that had naloxone “in
stock” or were “able to order” on the day of inquiry.

Independent Variables
•

Retail pharmacy type was determined post collection by reviewing the pharmacy roster
from the Georgia Board of Pharmacy. Pharmacies were classified as chain, independent,
or neither based on the amount of locations in the state. Following previous research,
chain pharmacies were labeled as such if they had four or more locations across the state
(Stone et al., 2019). Independent pharmacies were defined as those that had less than four
locations across the state. Pharmacies that either were not accessible by potential
customers from the street, such as pharmacies that were part of a hospital system or were

52
specialty pharmacies (home health care, compounding, hospice), were labeled “other”
and excluded from analyses.
•

The 2013 Rural-Urban Continuum Codes (RUCCs) were used for sampling retail
pharmacies in this study and to compare naloxone availability between urban and rural
areas of the state. RUCCs were created in 1973 to provide a classification that
distinguishes metropolitan counties by the population size of their metro area and
nonmetropolitan counties by the degree of urbanization and adjacency to a metro area (U.
S. Department of Agriculture, 2013a). These codes divide areas into three metro and six
non-metro categories, with each U.S. county being assigned a code. Table 3.1 includes
information about the codes. For sampling purposes, codes were grouped into three
strata: strata 1 included codes 1-3; strata 2 included codes 4-6; and strata three will
included codes 7-9 (Graves et al., 2019).
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Table 3.1
2013 USDA Rural-Urban Continuum Codes
Code

Description
Metropolitan Countiesa

1

Counties in metro areas of 1 million population or more

2

Counties in metro areas of 250,000 to 1 million population

3

Counties in metro areas of fewer than 250,000 population
Non-metropolitan Counties

a

4

Urban population of 20,000 or more, adjacent to a metro area

5

Urban population of 20,000 or more, not adjacent to a metro area

6

Urban population of 2,500 to 19,999, adjacent to a metro area

7

Urban population of 2,500 to 19,999, not adjacent to a metro area

8

Completely rural or less than 2,500 urban population, adjacent to a metro area

9

Completely rural or less than 2,500 urban population, not adjacent to a metro area

Metropolitan area are based on the Office of Management and Budget (OMB) delineation as of February

2013. See: http://www.census.gov/population/metro/data/metrodef.html

•

County-level five-year median household income data from the U.S. Census Bureau’s
American Community Survey (ACS) was used. The ACS is an annual nationwide survey
that collects information on social, economic, housing, and demographic characteristics
about the U.S. population. The ACS provides useful statistics about the median income of
an area. As many of Georgia’s counties are rural and have smaller population bases, fiveyear median annual household income estimates were used for the period from 2014 to
2018. These five-year estimates increase statistical reliability for smaller areas and
populations (U.S. Census Bureau, n.d.).
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•

County five-year age-adjusted opioid overdose death rates were obtained from the
Georgia Department of Public Health through the Online Analytical Statistical
Information System (OASIS). OASIS is a standardized health data repository maintained
by the Georgia Department of Public Health. It is populated with vital statistics (births,
deaths, fetal deaths, induced terminations, pregnancies), hospital discharge, emergency
room visit, Youth Risk Behavior Survey (YRBS), Behavioral Risk Factor Surveillance
Survey (BRFSS), sexually transmitted disease, motor vehicle crash, and population data.
Death rates for counties with four or fewer deaths are censored. Due to the amount of
deaths in some Georgia counties, death rates may be suppressed and not available for all
years. To address suppressed rates, aggregate five-year opioid overdose death rates were
used for this analysis for the period 2014 - 2018. Age-adjusted rates were used to control
for differences in age structures across counties so that observed differences in rates
across counties are not due solely to differences in the proportion of people in different
age groups in different areas.

•

County political leaning was determined data from the Atlas of U.S. Presidential
Elections, which aggregates official election results from all 50 states and the District of
Columbia (Leip, 2020). Political leaning was categorized as either republican or
democrat, based on county-level voting results from the 2016 presidential election.

Population, Survey Sample, and Recruitment
This study's target population was retail pharmacies licensed and located in the state of
Georgia (N = 1,389) as of February 2020. The sampling frame is the pharmacy roster from the
Georgia Board of Pharmacy. Pharmacies were not recruited and were selected from a listing of
active retail pharmacies across the state. Strata were determined based on USDA 2013 Rural-
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Urban Continuum Codes, which classifies counties based on population sizes of metro areas,
degree of urbanization, and adjacency to metro and non-metro area (U. S. Department of
Agriculture, 2013b). This sample was influenced by a few practical issues, including access to
resources to conduct this research and costs associated with data collection. Based on previous
research in Georgia that demonstrated as few as 37% and as many as 54.7% of pharmacies had
naloxone in stock, the sample size range required to estimate the expected proportion with a 5%
absolute precision and 95% confidence was 285 – 301 pharmacies (Dhand & Khatkar, 2014). To
ensure equal representation of each group of RUCCs, and to also account for pharmacies that
might not respond, 360 pharmacies were sampled. This sample includes the maximum amount of
pharmacies needed to sample, with an additional 20% added to the sample to account for nonresponsive pharmacies and ensure equal representation. Of the 1,389 retail pharmacies in the
target population, 987 (71%) are in RUCCs 1-3, 266 (19%) are in RUCCs 4-6, and 136 (10%)
are in RUCCs 7-9. Based on a sample of 360 retail pharmacies, the following number of
pharmacies were sampled for each stratum: 255 in strata 1 (RUCCs 1-3), 69 in strata 2 (RUCCs
4-6), and 36 in strata 3 (RUCCs 7-9). A stratified random sample of the three strata was taken
using Microsoft Excel version 16.0. As most of Georgia is classified as rural, a stratified
sampling approach using RUCCS was employed to ensure proportionate representation of a
continuum of counties and not just strictly urban or strictly rural counties. Figure 3.1 illustrates
the sampling strategy utilized for this research.
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Figure 3.1
Sampling Strategy
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Instrumentation
The survey instrument was informed by similar peer-reviewed research conducted in
California (Puzantian & Gasper, 2018), Texas (Evoy et al., 2018), and North Carolina (K. Egan,
2019). The survey instrument questions, along with the research informing each question, are
included in Appendix B.
Data Collection and Management
The survey instrument was administered via telephone using the contact information
available from an active list of pharmacies as of February 2020 from the Georgia Board of
Pharmacy. Seven data collectors surveyed pharmacies during August 2020. Data collectors were
trained before data collection to review the background and purpose of the study, collection
protocols, and review the customized Google Form. Practice calls were also conducted with
pharmacies not included in the sample to ensure the form operated as expected. Survey questions
were asked and recorded using a customized Google Form. During the collection period, data
collectors met to discuss and process any issues with data collection. Data collectors also
consulted with the lead investigator as needed to address real-time issues in collection. A Google
Form was used to ensure ease of reporting access for interviewers across geographic locations.
Data from the Google Form was populated into a master spreadsheet for analysis using SPSS
version 27. No sensitive information was collected from pharmacies or pharmacy staff. Data was
stored on a secure, password-protected personal computer and backed up using Google Drive
services available through Georgia Southern University.
Data Analysis
Data were analyzed using SPSS version 27 software. Descriptive analyses were
completed to provide aggregate data for survey questions and answer Research Question 1
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related to naloxone availability. For Research Question 2, chi-square tests of independence were
conducted to determine associations between naloxone availability, and pharmacy and
community-level variables. Test assumptions were checked before performing analyses. This test
requires two variables measured at the categorical level, independence of observations, and
cross-sectional sampling when collecting data. For the fourth assumption, which requires that all
cells have expected counts greater than or equal to five, one variable did not meet that
requirement (urbanicity). For that variable, Fisher’s Exact Test was used to determine
associations with naloxone availability. For Research Question 3, a multiple logistic regression
analysis was conducted to determine how well naloxone availability could be predicted by
pharmacy and community-level factors, which include retail pharmacy urbanicity (according to
RUCCs), community need (opioid overdose deaths), pharmacy type (chain vs. independent),
income, and political leaning. The following general multiple logistic function was used to
predict the probability of naloxone availability:

𝑃(𝑌) =

1
1+

𝑒 − (𝐴+𝐵1 𝑋1+𝐵2 𝑋2 +⋯+ 𝐵𝑛 𝑋𝑛 + 𝜀𝑖 )

where Y is the dependent variable, e is the base of natural logarithms, Bn denotes variable
coefficients, and Xn denotes independent variables included in the model. Applying this general
function to this research using the policy implementation framework, the following variables are
included:

𝑃(𝑠𝑒𝑙𝑙𝑛𝑎) =

1
1 + 𝑒 − (𝐴+𝐵1 𝑜𝑑𝑑𝑒𝑎𝑡ℎ𝑟𝑎𝑡𝑒+𝐵2 ℎℎ𝑖𝑛𝑐𝑜𝑚𝑒𝑐𝑜𝑢𝑛𝑡𝑦 + 𝐵3𝑝ℎ𝑎𝑟𝑚𝑡𝑦𝑝𝑒+ 𝐵4𝑟𝑢𝑐𝑐_𝑔𝑟𝑜𝑢𝑝+ 𝐵5𝑝𝑜𝑙𝑖𝑡_𝑙𝑒𝑎𝑛)
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Two values for naloxone availability (variable label: sellna) were included: “0” for not
available (noted as not in stock on the day of inquiry and not available to order) and “1” for
available (in stock on the day of inquiry or available for ordering). For variables, five-year ageadjusted opioid overdose deaths by county (variable label: oddeathrate), five-year median annual
household income estimates (variable label: hhincome_county), retail pharmacy type (variable
label: pharmtype), retail pharmacy urbanicity based on RUCCs (variable label: rucc_group), and
county political leaning (variable label: polit_lean) were included in the model. A full multiple
logistic regression model was created, and variables were reviewed for statistical significance. A
p-value less than .05 was considered statistically significant. Variables included in the model,
data sources, and type are summarized in Table 3.2.

Table 3.2
Study Variables, Data Sources, and Type
Variable

Source

Type

Naloxone availability

Survey

categorical

County five-year age-adjusted opioid overdose
deaths

Georgia OASIS

continuous

County median household income

American Community Survey

continuous

Pharmacy urbanicity and rurality

USDA Rural-Urban Continuum Codes

categorical

Pharmacy type

Board of Pharmacy Roster

categorical

Political leaning

U.S. Election Atlas

categorical

Ethical Considerations and Informed Consent
This study did not involve subjects enrolled in experimental protocols and posed no risk
to pharmacy staff. Although there was no risk to pharmacy staff, pharmacy locations' identities
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were protected by conducting aggregate analyses, identifying pharmacies by pharmacy type,
urban and rural classification, and county. Identifying information for each pharmacy was
removed before analysis to ensure no address, zip code, or other contact information was shared.
This research was approved by the Georgia Southern University Institutional Review Board. A
waiver of consent was also requested and approved by GSU IRB. IRB approval documentation is
included in Appendix A.
Limitations
This research has at least four limitations. First, this study was conducted 44 months
years after implementation of Georgia’s standing order for naloxone. Although the delayed
evaluation of the implementation of a policy increases the likelihood of seeing the impact, the
number of years since implementation could also introduce other programs and policies that
could potentially impact naloxone availability, making it more difficult to account for all
possible effects.
Second, this research did not seek to provide information on all retail pharmacies in the
state and sampled a proportion of pharmacies. This introduces sampling bias, which was
accounted for using a stratified random sampling technique that mirrored the proportion of urban
and rural pharmacies in the state based on RUCCs.
Third, data collection biases could also be present. There were seven different data
collectors used to conduct this research. This was mitigated by conducting training on data
collection protocols, conducting practice calls, and having a mid-collection meeting to address
any potential issues. The first meeting was held to provide training on data collection protocols
and processes. The second collection meeting was held pre-collection to discuss the collection
process methodology and data collection form. During the data collection period, the third
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meeting was held to discuss collector progress and address any issues that arose during calls.
During the collection period, data collectors consulted with the lead investigator to address realtime issues in collection.
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CHAPTER 4
RESULTS
This chapter presents results from data analyses for this study, beginning with descriptive
statistics for survey data to describe the study variables overall and by strata. Next, chi-square
results are presented to describe associations between naloxone availability and pharmacy and
community-level factors. Last, binary logistic regression analysis results are presented. This
study sought to describe naloxone availability in retail pharmacies across the state of Georgia 44
months after implementation of the state’s naloxone standing order. It also sought to analyze
associations and predict naloxone availability based on pharmacy and community-level factors.
This chapter presents the analysis results to answer each study aim.
Descriptive Statistics
Of the 360 pharmacies contacted, 314 were considered responsive. Non-responsive
pharmacies were either: 1) not available by phone after multiple contact attempts; or 2) did not
have a working number. Of the 314 pharmacies that were responsive, 145 were chain
pharmacies, 157 were independent, and 12 were other types of pharmacies (hospital, assisted
living, compounding, etc.). Misclassified pharmacies were initially contacted by phone but
excluded from analysis because they had been classified as a retail pharmacy when they were
another type of pharmacy. In total, 302 pharmacies were included in the analyses. Figure 4.1
summarizes the pharmacies sampled from the Georgia Board of Pharmacy Roster. Percentages
are included and calculated based on the total number of pharmacies contacted (n = 360). Figure
4.1 summarizes sample characteristics.
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Figure 4.1
Sample Characteristics

Note. Non-responsive pharmacies and pharmacies that were “other” types (not retail or did not service community
members) were excluded from analysis. Percentage are calculated based on the total sample (n = 360).

Regarding pharmacy type, 135 (43%) of pharmacies were chain pharmacies, and 167 (53.2%)
were independent pharmacies with less than four locations (Stone et al., 2019). A total of 226
pharmacies were in counties classified as RUCC Group 1 (RUCCs 1-3), 50 in RUCC Group 2
(RUCCs 4-6), and 26 in RUCC Group 3 (RUCCs 7-9). Across the sample, the median household
income of the counties in which each pharmacy was located was $57,049. For reference, the state
median household income is $55,679. County age-adjusted opioid overdose death rates were
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included for 278 pharmacies, with rates excluded for pharmacies in counties with four or fewer
cases. The median county opioid overdose death rate for these pharmacies was 8.5 per 100,000.
The two continuous variables in this study (county annual median household income and county
age-adjusted opioid overdose death rates) were grouped based on the distribution of observed
values. Income was grouped into low, medium, and high categories based on tertile values.
Opioid overdose death rates were classified as low or high based on a median split (Stone et al.,
2019). The “low” category includes opioid overdose death rates less than or equal to 8.5. The
“high” category includes opioid overdose death rates greater than or equal to 8.51. Forty-seven
percent of pharmacies (47%) were in counties with a democratic political leaning, while 53% of
pharmacies were in counties with a republican political leaning.
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Table 4.1
Counts of Retail Pharmacies Included in Analyses
Characteristic

n

(%a)

Pharmacy type

302

(100)

Chain

135

(45)

Independent

167

(55)

302

(100)

1–3

226

(75)

4–6

50

(17)

7–9

26

(9)

302

(100)

1st tertile (low, <$45,389)

103

(34)

2nd tertile (medium, $45,359 – $64,787)

117

(39)

3rd tertile (high, > $64,787)

82

(27)

278

(100)

Low (≤ 8.5)

142

(51)

High (>8.5)

136

(49)

302

(100)

Democrat

142

(47)

Republican

160

(53)

RUCC Groups (Strata)

County five-year median household income

Age-adjusted five-year opioid overdose death rate (per 100,000)

Political leaning

a

Percentages are based on the total number included for analysis in each category (n=302 or

n=278).

The sample was stratified by USDA Rural-Urban Continuum Codes to ensure that it was
representative of both urban and rural pharmacies in Georgia. Tables 4.2 and 4.3 provides
descriptive statistics based on RUCC strata.
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Table 4.2
Descriptive Characteristics of Categorical Variables by USDA Rural-Urban Continuum Codes
RUCC Group 1

RUCC Group 2

RUCC Group 3

(n = 255)

(n = 69)

(n = 36)

n

n (%)

n (%)

n (%)

302

226 (74.8)

50 (16.6)

26 (8.6)

Chain

145

123 (84.8)

17 (11.7)

5 (3.4)

Independent

157

103 (65.6)

33 (21)

21 (13.4)

Democrat

142

137 (96.5)

5 (3.5)

0 (0)

Republican

160

89 (55.6)

45 (28.1)

26 (16.3)

Characteristic
Responsive pharmacies
Pharmacy Type

Political leaning

Note: Percentages are calculated based on row totals. For example, of the 145 chain pharmacies included in
the analysis, 84.8% are in RUCC Group 1.

Table 4.3
Descriptive Statistics of Continuous Variables by USDA Rural-Urban Continuum Codes
RUCC Group 1

RUCC Group 2

RUCC Group 3

(n = 255)

(n = 69)

(n = 36)

Mean

60,895

40,480

37,413

Median

59,898

39,887

37,595

Standard deviation

13,087

5,348

4,086

Mean

8.6

8.7

8.8

Median

8.4

8.5

8.3

Standard deviation

2.9

3.2

3.4

Median household income

Age-adjusted opioid overdose death rate
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Research Aim 1 Results
Research Aim 1 sought to describe and explore naloxone availability within the state of
Georgia, 44 months after implementation of the statewide standing order. The objective of the
first research aim is to provide descriptive data on naloxone availability 44 months after the
passage of Georgia’s naloxone standing order, describing differences based on urbanity,
pharmacy type, opioid overdose death rates, household income, and county political leaning.
Research Question 1 (Availability): What is the Availability of Naloxone in Retail Community
Pharmacies 44 months After the Implementation of Georgia’s Naloxone Standing Order?
Descriptive statistics and survey responses are presented in Table 4.4. Of the 302
pharmacies that were analyzed, 247 (81.8%) indicated that naloxone was available either for
immediate pick-up or to order. More than half (69.2%) of pharmacies had naloxone in stock and
available for immediate pick-up, while 30.8% indicated they could order naloxone. A
prescription was not needed for 95 (41.9%) of pharmacies. Of the pharmacies that did not have
naloxone on hand at the time of inquiry, 51 (67.1%) indicated they could order and have it
available in less than 24 hours. The remaining 25 (32.9%) pharmacies that did not have naloxone
on hand and could order it indicated that it would take 24-48 hours to order and receive naloxone
in the pharmacy for pickup. Only 13.3% of pharmacies had other types of naloxone available
under the state-wide standing order across the entire sample.
Regarding pharmacy type, chain pharmacies (93.8%) had a higher percentage of
naloxone availability than independent pharmacies (45%). No prescription was needed in 46.6%
of chain pharmacies, compared to 35.4% of independent pharmacies. If naloxone had to be
ordered by a pharmacy that did not have it in stock, 61.9% of chain pharmacies could have
naloxone available within 24 hours, and 38.1% could have it available between 24 – 48 hours.
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For independent pharmacies, 69.1% of pharmacies that had to order it because it was not in stock
on the day of inquiry said they could have it available within 24 hours, while 30.9% of those that
had to order it could have it available in 24 – 48 hours. Other naloxone types were available in
13.3% of chain pharmacies compared to 13.4% of independent pharmacies.
When comparing RUCC strata, the percentage of pharmacies within RUCC strata with
naloxone available was highest with pharmacies in Group 3 (84.6%), although the actual number
of pharmacies was lowest (22) compared to other strata. Of the pharmacies in RUCC Group 1,
82.3% of pharmacies had naloxone available. In RUCC Group 2, 78% of pharmacies had
naloxone available. For RUCC Group 1, 43.3% of pharmacies noted that a prescription was not
required to get naloxone. In RUCC Group 2, 30.6% of pharmacies noted no prescription was
needed for pickup, while half (50%) in RUCC Group 3 noted that prescriptions were not needed
for pickup. If naloxone had to be ordered, 71.4% of pharmacies in RUCC Group 1, 66.7% in
Group 2, and 37.5% in Group 3 noted it could be available in less than 24 hours. For availability
within 24 – 48 hours, 26.8% in Group 1, 33.3% in Group 2, and 62.5% in Group 3 noted it could
be available in that timeframe. Lastly, RUCC Group 3 had the highest percentage of other
naloxone types available at 15.4%, compared to 10% in Group 2 and 13.8% in Group 1.
Of the pharmacies in the low opioid death rate group, 78.2% of pharmacies had naloxone
available. In the high category, 84.6% of pharmacies had naloxone available. Regarding
requiring a prescription, 50.5% of pharmacies in the low category and 33.3% of pharmacies in
the high category required a prescription. When naloxone had to be ordered, it was available
within 24 hours in 61.3% of pharmacies in low rate counties and 73% of pharmacies in high rate
counties. Lastly, 9.9% of pharmacies in low rate counties had other types of naloxone available,
while 14.8% of pharmacies in high rate counties had other types of naloxone available.
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For pharmacies in the low-income group, 79.6% of pharmacies had naloxone available.
In the medium income group, 81.2% of pharmacies had naloxone available. In the high-income
group, 54.4% of pharmacies had naloxone available. Approximately 40% of pharmacies in the
low-income group did not require a prescription, compared to 44.8% in medium-income counties
and 56.3% in high-income counties. For those that did not have naloxone available and could
order it, 57.1% in low, 72.4% in medium, and 73.7% in high-income counties could have it
available within 24 hours. For availability within 24-48 hours, 42.9% in low, 27.6% in medium,
and 26.3% in high-income counties could have it available in that timeframe. Regarding other
naloxone types, 14.6% of pharmacies in low, 10.3% in medium, and 16% in high-income
counties had other types of naloxone available.
Political leanings of the counties in which pharmacies are located were also explored.
Naloxone was available in 76.1% of pharmacies in democratic-leaning counties, compared to
86.9% in republican-leaning counties. No prescription was required in 43.6% of pharmacies in
democratic-leaning counties compared to 40.5% in republican-leaning counties. If the pharmacy
had to order naloxone, 68.8% of pharmacies in democratic-leaning counties noted it would be
available in less than 24 hours. In republican-leaning counties, 65.9% of pharmacies noted the
same. For naloxone to arrive within 24 – 48 hours, 31.3% of pharmacies in democratic-leaning
counties and 34.1% in republican-leaning counties noted that naloxone would be available.
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Table 4.4
Naloxone Availability and Pharmacy Staff Responses by Pharmacy and Community-Level Variables
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Table 4.5 includes summary information regarding cost for naloxone. Because cost
information was not shared with data collectors uniformly across pharmacies, these results are
included in a separate table. For Narcan, which is the most common form of naloxone available
to consumers, the mean price was $148. The most frequently quoted price was $150. Prices
ranged from $67.99 – $329.95. For the Narcan syringe, the mean price was $140. The most
frequently quoted price was $40. Prices for the Narcan syringe ranged from $21.99 to $399. For
EVZIO, only two pharmacies provided price information ($40 and $300). Since the price data for
EVZIO is bimodal, only the range is included.

Table 4.5
Naloxone Cost by Type
Type

n

Mean ($)

Median ($)

Mode ($)

Range ($)

Narcan

219

148.00

142.99

150.00

67.99 – 329.95

Narcan Syringe

12

140.00

70.00

40.00

21.99 – 399.00

EVZIOa

2

170.00

–

–

40.00 – 300.00

Note. Values are in U.S. dollars.
a

Price information for EVZIO was only provided by two pharmacies in the sample. Median or

mode values are not reported. The reported range includes the two prices reported.

Additional information offered by staff was noted during data collection. Although not
explicitly included in analyses, this information does provide pertinent insight into naloxone
availability. Staff noted on some calls that a prescription was needed for naloxone unless it was
being picked up with an opioid prescription. Some staff also volunteered prices for naloxone
before data collectors could ask. Unsolicited patient assistance and prescription discount program
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information was offered by some staff. Although data collectors were calling as patients with no
insurance, pharmacy staff noted the need for a prescription to bill insurance plans. Lastly, staff
offered specific resources to get access to naloxone (naloxoneexchange.com and surrounding
pharmacies).
Research Aim 2 Results
The second research aim research sought to examine pharmacy and community-level
factors identified in the literature for association with naloxone availability and for usefulness in
predicting availability.
Research Question 2 (Associations with Availability): What Pharmacy and Community-Level
Factors Are Associated with Naloxone Availability 44 Months After the Implementation of
Georgia’s Naloxone Standing Order?
To determine the level of association between the pharmacy and community-level
variables and naloxone availability, chi-square tests and a logistic regression analysis were
conducted.
Chi-square tests of independence were performed for each variable to examine the
relationship between naloxone availability (outcome) and pharmacy and community-level factors
(independent variables). This analysis was conducted to provide the most appropriate measure of
association with the data. Chi-square statistics are reported in Table 4.6. Assumptions to consider
before conducting a Chi-square test include: 1) having two nominal variables; 2) independence
of observation, meaning there are different individuals in each group; 3) study design; and 4)
expected cell counts should be greater than or equal to 5. All assumptions for this test were met
for four variables: pharmacy type, median household income, political leaning, and age-adjusted
opioid overdose death rates. For urbanicity, expected cell counts for at least one cell in the cross-
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tabulation table was below 5. For this variable, Fisher’s Exact Test was used to determine
associations.

Table 4.6
Chi-Square (χ2) Analysis Results
χ2*

df

p-value

n

φa

Pharmacy type

26.99

1

<.0005*

302

.299

Urbanicity (RUCC groups)b

.689

2

.741

302

.047

Age-adjusted opioid overdose death ratesc

1.865

1

.172

278

.082

Median household income

1.060

2

.589

302

.140

Political leaning (Republican)

5.912

1

.015*

302

.140

Variable

a

Cramer’s V is reported when both variables have two categories (pharmacy type, political leaning, and

opioid overdose death rates). For urbanicity and median household income, Phi is reported. bFisherFreeman-Halton Exact Test used because one cell in the contingency table for RUCC groups had an
expected value of less than 5. cThe n value for age-adjusted opioid overdose death rates was 278 due to
missing rates for counties with four or less opioid overdoses.
*p<.05

A multiple logistic regression model was created using a forced entry approach, including
all variables into the initial model to determine how well naloxone availability is predicted by
pharmacy and community-level factors in this study. This method was used because previous
research has demonstrated relationships between the independent variables in this study and
naloxone availability. The logistic regression analysis included 278 pharmacies for which
complete data was available. Twenty-four pharmacies were not included in the regression
analysis because opioid overdose death data was not available for the county in which the
pharmacy was located. The dependent variable in the multiple logistic regression analysis is the
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availability of naloxone, noted as either “available” or “not available.” The “available” category
includes pharmacies that either had naloxone available at the time of inquiry or could order it.
“Not available” includes pharmacies that could not order naloxone or did not sell it.
All assumptions for this test were met. The first five assumptions are addressed and met
by the study design and include: 1) one dichotomous dependent variable; 2) one or more
nominal or continuous independent variables; 3) independence of observations; 4) mutually
exclusive categories for the dichotomous dependent variable and all nominal dependent
variables; and 5) a minimum of 15 cases per independent variable. Additional assumptions were
checked during preliminary analyses. They include a linear relationship between the continuous
dependent variables and the logit transformation of the dependent variable, multicollinearity, and
significant outliers.
Linearity of the continuous variables with respect to the logit of the dependent variable
was assessed via the Box-Tidwell procedure, which is a transformation used to change predictor
variables so that the relationship between the predictor and the outcome resembles a straight line
(Box & Tidwell, 1962). A Bonferroni correction was applied using all ten terms (including the
constant) in the model resulting in statistical significance being accepted when p < .005
(Tabachnick & Fidell, 2013). Based on this assessment, all continuous independent variables had
significance values greater than .005 and were found to be linearly related to the logit of the
dependent variable.
Multicollinearity, which occurs when two or more independent variables are highly
correlated with each other, was assessed through an inspection of Tolerance and Variance
Inflation Factor (VIF) values and coefficient collinearity. Tolerance values less than .1 indicate a
problem with collinearity (Menard, 2001). VIF values greater than ten also indicate collinearity
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(Myers, 1990). All independent variables in the model had tolerance values more than .1 and VIF
values less than 10. A table of values are included in Appendix C. Multicollinearity was also
tested by assessing individual variable pairs. A correlation matrix is included in Appendix D.
To test for outliers, standardized residuals were calculated. There were nine standardized
residuals higher than 2.5. The regression analysis was rerun, with two additional standardized
residuals higher than 2.5. Upon review of the outliers noted in the first and second regression
analysis, none of the cases appeared to have the highest or lowest values for neither county
median household income nor county age-adjusted opioid overdose death rates and are not
believed to be true outliers. Based on this assessment, all cases were kept in the analysis.
Regression results are included in Table 4.7, with significant variables at the 0.05 level
highlighted.
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Table 4.7
Multiple Logistic Regression Model Predicting Naloxone Availability
β

SE β

Wald’s

df

p

Odds Ratioa

Constant

-.902

1.033

.763

1

.382

Pharmacy type (Chain)

2.041

.406

25.262

1

RUCC Group 1a

-

-

1.294

RUCC Group 2

-.497

.572

RUCC Group 3

.322

95% CI OR
LL

UL

.406

-

-

<.0005*

7.697

3.473

17.058

2

.524

-

-

-

.757

1

.384

.608

.198

1.865

.914

.124

1

.725

1.379

.230

8.267

.098

.066

2.207

1

.137

1.103

.969

1.256

Household income

<.0005

<.0005

.201

1

.654

1.000

1.000

1.000

Political leaning (Republican)

1.042

.423

6.074

1

.014*

2.834

1.238

6.488

County urbanicity

Opioid overdose death rate

Note: R2 = 12.710 (Hosmer & Lemeshow), .237 (Nagelkerke). -2LL = 223.901. OR = odds ratio. CI = confidence interval. LL = lower limit. UL
= upper limit.
a

RUCC Group 1 is the reference group for the county urbanicity variable.

*p<.05
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Naloxone Availability and Pharmacy Type. A chi-square test of independence was
conducted between naloxone availability and pharmacy type. All expected cell frequencies were
greater than five. The relationship between these variables was significant, χ2(1, N = 302) =
26.99, p<.0005 (Table 4.6). The association is moderately strong (Cohen, 2013), Cramer’s V =
.299. Therefore, the null hypothesis is rejected, and the alternative hypothesis is accepted. The
multiple logistic regression analysis also showed pharmacy type to be statistically significant in
predicting naloxone availability. Chain pharmacies (OR = 7.697, 95% CI [3.473, 17.058]) were
statistically significant in the model, which confirms associations presented in chi-square
analysis results (Table 4.7). Chain pharmacies are 7.697 times more likely to have naloxone
available than independent pharmacies.
Naloxone Availability and Urbanicity. A chi-square test of independence was
conducted between naloxone availability and urbanicity (based on RUCC groups). One of the
expected cell frequencies was less than 5, so the Fisher-Freeman-Halton Exact Test was used and
is reported in Table 4.5. There was no statistically significant association between naloxone
availability and pharmacy urbanicity/rurality (p = .741) (Table 4.6). This research fails to reject
the null hypothesis that there are no associations between naloxone availability and urbanicity.
Logistic regression results also confirm chi-square analysis results and did not show urbanicity to
be a statistically significant factor in predicting naloxone availability, RUCC Group 2 (vs. RUCC
Group 1) (OR = .608, 95% CI [.198, 1.865]), or RUCC Group 3 (vs. RUCC Group 1) (OR =
1.379, 95% CI [.230, 8.267]) (Table 4.7).
Naloxone Availability by County Age-Adjusted Opioid Overdose Death Rates. A
chi-square test of independence was conducted between naloxone availability and county ageadjusted opioid overdose death rates. There was no statistically significant association between
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naloxone availability and opioid overdose death rates, χ2(1, N = 278) = 1.865, p = .172) (Table
4.6). This research fails to reject the null hypothesis that there are no associations between
naloxone availability and opioid death rates. Logistic regression results confirm chi-square
analysis results and did not show county age-adjusted opioid overdose death rates to be a
statistically significant factor in predicting naloxone availability (OR =1.103, 95% CI [.969,
1.256]) (Table 4.7).
Naloxone Access and County Median Household Income. A chi-square test of
independence was conducted between naloxone availability and county median household
income.. The relationship between these variables was not significant, χ2(2, N = 302) = 1.060, p
= .589 (Table 4.6). Therefore, this research fails to reject the null hypothesis that there is no
association between the two variables. Logistic regression results confirm chi-square analysis
results and did not show county median household income to be a statistically significant factor
in predicting naloxone availability (OR =1, 95% CI [1,1]) (Table 4.7).
Naloxone Availability by Political Leaning. A chi-square test of independence was
conducted between naloxone availability and county political leaning. All expected cell
frequencies were greater than five. The relationship between these variables was significant,
χ2(1, N = 302) = 5.912, p = .015. The association was small (Cohen, 2013), Cramer’s V = .140.
Therefore, the null hypothesis is rejected, and the alternative hypothesis that there is an
association between naloxone availability and county political leaning is accepted. Pharmacies in
republican-leaning counties (OR = 2.834, 95% CI [1.238, 6.488]) were statistically significant in
the logistic regression model, which confirms associations demonstrated in chi-square analysis
results. Pharmacies in republican-leaning counties are 2.834 times more likely to have naloxone
available than pharmacies in democratic-leaning counties.
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As demonstrated, urbanicity, age-adjusted opioid overdose death rates, and county
median household income were not associated with naloxone availability. Pharmacy type and
political leaning are both associated with naloxone availability. The next section of the analysis
tests a model to predict naloxone availability.
Research Question 3 (Predicting Availability): How Well Can Naloxone Availability Be
Predicted Based on Retail Pharmacy Type, Rurality/Urbanicity, Opioid Overdose Deaths,
Median Household Income, and Political Leaning?
To answer Research Question 3, a multiple logistic regression was performed to test a
model that predicts naloxone availability based on pharmacy type, urbanicity, opioid overdose
death rates, income, and county political leaning. Multiple logistic regression results are included
in Table 4.7. Using the Omnibus Tests of Model Coefficients, model fit was assessed to describe
how well the model with variables predicts categories compared to the constant-only model. The
multiple logistic regression model was statistically significant, χ2 (6) = 44.045, p<.0005. The
Hosmer and Lemeshow Goodness-of-Fit Test provides another method of assessing model
adequacy by analyzing how poor the model is at predicting outcomes. This test was not
statistically significant, χ2(8) = 3.83, p = .871, which indicates that the model is not a poor fit.
The model explained 23.7% (Nagelkerke R2) of the variance in naloxone availability and
correctly classified 82% of cases. Based on these results, the alternative hypothesis that naloxone
availability can be predicted based on retail pharmacy type, rurality/urbanicity, opioid overdose
deaths, median household income, and political leaning is supported.
Summary
Statistical tests were conducted to describe naloxone availability in Georgia retail
pharmacies 44 months following the implementation of a statewide standing order; examine
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select factors associated with naloxone availability (pharmacy type, urbanicity, opioid overdose
death rates, income, and county political leaning); and determine how well select factors can
predict naloxone availability. Descriptive analyses were conducted to describe current naloxone
availability. Chi-square analyses were conducted to determine associations between select
factors and naloxone availability. Finally, a multiple logistic regression was performed to
determine how well select factors predict naloxone availability. Naloxone availability was
assessed via a phone survey using a simulated client approach. Along with survey data,
pharmacy and community-level factors were included in analyses and analyzed with survey data
to describe naloxone availability, determine associations between selected variables and
naloxone availability, and determine how well the selected variables might predict naloxone
availability. The two statistically significant factors that were found to be associated with and
significant predictors of naloxone availability were the pharmacy type and county political
leaning. The multiple logistic regression model explained 23.7% of the variation in naloxone
availability.

81

CHAPTER 5
DISCUSSION
Increasing naloxone availability remains an important strategy in reversing the effects of
opioid overdoses. The purpose of this study was to describe and analyze factors associated with
naloxone availability in Georgia. A simulated client methodology was used to collect data about
naloxone availability 44 months after implementation of the state’s standing order for naloxone.
Analyses were conducted using survey data and other publicly available data sources.
Descriptive analyses were conducted to describe naloxone availability. Chi-square and multiple
logistic regression analyses were used to assess associations between the pharmacy and
community-level factors identified in the literature and naloxone availability. Multiple logistic
regression was also used to develop a model to predict naloxone availability. As a result,
pharmacy type and county political leaning were significantly associated with and predictors of
naloxone availability. The pharmacy and community-level factors included in the multiple
logistic regression model created a statistically significant model to predict naloxone availability
in Georgia. Findings are presented by research aim in the following text. Where appropriate and
possible, comparisons are made to previous research.
Research Aim 1: Describe and Explore Naloxone Availability within Georgia
Research Question 1 sought to describe and explore naloxone availability 44 months after
implementation of Georgia’s naloxone standing order, exploring the following factors: pharmacy
type, urbanicity, opioid overdose death rates, median household income, and political leaning.
General Naloxone Availability
Naloxone availability has improved since implementation of Georgia’s standing order,
with 81.8% of pharmacies with naloxone in stock or able to order based on this study’s results.
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Previous research of naloxone availability in Georgia noted that in 2019, naloxone was available
in 54.7% of Georgia pharmacies (Nguyen et al., 2020). In 2017 (shortly after implementation of
Georgia’s standing order), naloxone was available in 31.1% of Georgia pharmacies (Stone et al.,
2019). Studies across the country have shown that naloxone availability varies, with about 33%
of pharmacies stocking or dispensing naloxone (Lozo et al., 2019), to approximately half of
pharmacies (Graves et. al., 2019; Correal, 2018; Meyerson et al., 2018; Puzantian & Gasper,
2018; Sisson et al., 2019) to approximately 75% of pharmacies (Evoy et al., 2018). More than
half of pharmacies required a prescription, even though Georgia’s standing order has been in
place since December 2016. Prescriptions were not needed in 41.9% of pharmacies, compared to
47.5% in the 2019 Georgia study (Nguyen et al., 2020). The literature shows that even after
standing order implementation, many pharmacists and pharmacy staff may be aware (Graves et
al., 2019; Guadamuz et al., 2019) or may not be aware (Correal, 2018; Evoy et al., 2018) of
naloxone availability under a standing order. This study did not seek to determine why a
prescription was needed, but this prescription requirement could be due to lack of standing order
knowledge, stigma related to opioid use disorder (Penm et al., 2017; Zaller et al., 2013), or
pharmacy policy. This study’s results for ordering naloxone showed that most pharmacies that
had to order naloxone could have it available within one business day (67.1%), with 32.9%
noting it would be available within 2 business days. For comparison, Graves et al. (2019)
reported that 57% of pharmacies that did not have naloxone in stock could have it available for
pickup within 1 business day, and 14% could have it available within 2 business days.
Pharmacy Type
Chain pharmacies had a higher percentage of naloxone availability compared to
independent pharmacies, which is consistent with previous research (Egan et al., 2020; Sisson et
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al., 2019). No prescription was needed in almost half of chain pharmacies (46.6%), with about
one-third of independent pharmacies reporting that no prescription was needed (35.4%). Both
chain and independent pharmacies had the same percentage of types of naloxone available. This
contrasts with reported differences in types of naloxone available, with chain pharmacies
carrying more than one type of naloxone (Sisson et al., 2019). It is important to note that rural
areas generally have more independent pharmacies, while urban areas have a higher
concentration of chain pharmacies. Chain pharmacies have organizational structures with
centralized management that allow for additional support to implement policies such as standing
orders. This could include training of requirements under standing orders, additional staff to
dispense naloxone, organizational requirements to comply with standing orders, and larger
geographic ranges to offer consistent access to naloxone. While independent pharmacies also
have access to training, lack of centralized management could result in varying levels of
implementation in areas with independent pharmacies, lack of staff to handle additional
dispensing demands, and no organizational requirements to comply with standing orders.
Urbanicity and Rurality
Study results show no large differences in naloxone availability in urban and rural areas
based on RUCC groupings. In pharmacies located in the most rural portions of the state, no
prescription was needed in half of the pharmacies, the highest percentage reported for any RUCC
group. Previous research also found no differences in dispensing in naloxone based on rurality,
yet rural pharmacies were less likely to have naloxone in stock, had fewer formulations in stock,
required more time to obtain naloxone, and offered less comprehensive training than urban
pharmacies (Sisson et al., 2019).
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Opioid Overdose Death Rates
Previous research has shown associations between naloxone availability and high opioid
overdose death rates (Stone et al., 2019). However, other research found no correlation between
state naloxone dispensing rates and state rates of opioid-related overdoses (Freeman et al., 2018).
In this study, there were no major differences in percentages reported for availability. Still, a
wider gap emerged between the percentage of pharmacies that did not require a prescription in
low death rate counties (50.5%) and high death rate counties (33.3%). Ordering time frame
percentages were not drastically different, but a difference emerged with other types of naloxone
available: 9.9% in low death rate counties and 14.8% in high death rate counties. This could
potentially put those in areas with higher burdens at risk because other less expensive
formulations of the drug may not available.
Naloxone Costs
Of the cost information gathered, the mean price for Narcan was $148, $170 for Evzio,
and $140 for the Narcan syringe. Previous research has reported while off-label use of injectable
naloxone for intranasal administration can be relatively low cost (approximately $40), Narcan
nasal spray cost $150 per two-dose pack in 2016, while the Evzio auto-injector two-pack cost
$4,500 that same year (Gupta et al., 2016). The price for Narcan found in this study is in line
with these previously reported figures. For the Evzio auto-injector, only two pharmacies
provided information for this type of naloxone, with very different prices.
Additional Information from Data Collection
Additional information offered by staff provides context into naloxone availability. Staff
noted on some calls that a prescription was needed for naloxone unless it was being picked up
with an opioid prescription. This could be due to recommendations from CDC’s opioid
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prescribing guidelines, which recommended naloxone co-prescription with high-dose opioids
and benzodiazepine use (Dowell et al., 2016). Unsolicited patient assistance and prescription
discount program information was offered by some staff. Although data collectors were calling
as patients with no insurance, pharmacy staff noted the need for a prescription to bill insurance
plans. Lastly, staff offered specific resources to get access to naloxone (naloxoneexchange.com
and surrounding pharmacies). This additional context is useful in determining additional factors
that may affect naloxone availability for future research.
Research Aim 2: Examine Pharmacy and Community-Level Factors Association with
Naloxone Availability and For Usefulness in Predicting Availability
Results demonstrated an association between both pharmacy type and county political
leaning, and naloxone availability. Chi-square analyses confirmed associations, and multiple
logistic regression results demonstrated that pharmacy type and county political leaning were
statistically significant predictors of naloxone availability. More specifically, chain pharmacies
and pharmacies located in republican-leaning counties were more likely to have naloxone
available. Previous research shows that retail/chain pharmacies were more likely to stock and
dispense than independent/local pharmacies (Egan, 2019; Graves et al., 2019; Guadamuz et al.,
2019; Meyerson et al., 2018; Sisson et al., 2019).
This study was the first to examine political leaning in relation to standing order
implementation. As previously mentioned, limited research is available to describe the
relationship between political preferences and harm reduction policies. The literature on partisan
preferences is mixed. Republicans are less supportive of treatment policies than Democrats
overall (De Benedictis-Kessner & Hankinson, 2019). However, anxiety can lead to more liberal
preferences, while fear may lead to conservative preferences among republicans (Kaufman &
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Hersh, 2020). This study also offers an additional independent non-statutory variable to be
explored with future research that could affect policy implementation and intended policy
outcomes.
This study did not find associations between pharmacy urbanicity, opioid overdose death
rates, and income, as positioned in the literature. Urbanicity was not associated with naloxone
availability, which is consistent with previous research showing no differences in dispensing
(Sisson et al., 2019) or availability (Puzantian & Gasper, 2018). This study’s results conflict with
Lozo et al. (2019), which reported a positive relationship with median household incomes and
naloxone availability in select New Jersey cities. This study’s findings also conflict with Stone et
al. (2019), which found that areas with high opioid death rates in Georgia were more likely to
have naloxone available at pharmacies.
The differences in this study's results and previously published literature could possibly
be attributed to a few matters. The first is that previous studies were conducted during different
time frames using different methods for different populations. Secondly, the opioid overdose
epidemic has had substantial federal funding, with an increase of 124% from 2017 ($3.3 billion)
to 2018 ($7.4 billion) alone (Bipartisan Policy Center, 2019). Increased funding to address
opioid overdoses and overdose deaths could have impacted states’ ability to provide access to
naloxone via pharmacies or by other avenues. This increased funding has brought with it
increased resources and attention, which has increased public expectations of naloxone
availability, with all states having some type of naloxone access law in place (Prescription Drug
Abuse Policy System, 2017), and multiple federal agencies noting naloxone availability as a vital
component of addressing the opioid overdose epidemic (Office of the Surgeon General, 2018; U.
S. Department of Health and Human Services, 2018; U.S. Department of Health and Human
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Services, 2015). Lastly, the timeframe for policy implementation could be a major factor in the
increased availability of naloxone in Georgia, and the variables that may affect the
implementation of the standing order. Mazmanian and Sabatier (1983) state that seven to ten
years is an appropriate time to analyze policies to correct deficiencies in legal frameworks and
test the ability of policies to develop and maintain political support over time. Georgia’s standing
order for naloxone has been in place for almost four years now. Although it has not been seven
to ten years, the timeframe to implement the policy has allowed for recognition of its presence
and has affected naloxone availability in the state.
Study Strengths and Limitations
This study shows that naloxone availability has increased in Georgia over time since the
standing order was implemented. This study also found that pharmacy type and political leaning
were both associated with and significant in predicting naloxone availability. Although this study
was conducted 44 months after standing order implementation, it has several notable strengths.
First, it provides up to date information about naloxone availability across both urban and rural
pharmacies in the state. Previous research published by Stone et al. (2019) and Nguyen et al.
(2020) found that the availability of naloxone in Georgia pharmacies was 31.1% in 2017 and
54.7% in 2019. This increased availability could be due to additional time to implement policy
and/or increased knowledge around Georgia’s standing order. In other state studies, naloxone
availability has ranged from about 33% of pharmacies stocking or dispensing naloxone (Lozo et
al., 2019) to approximately half of pharmacies (Correal, 2018; Meyerson et al., 2018; Puzantian
& Gasper, 2018; Sisson et al., 2019) to around 75% of pharmacies (Evoy et al., 2018).
Second, this study adds to the literature information regarding factors that may be
associated with and useful for predicting naloxone availability in Georgia. This research includes
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an analysis to predict availability based on pharmacy and community-level factors. This had not
been done in Georgia and was an area of future research, as noted by Nguyen et al. (2020). Other
state studies have had mixed results in factors that affect naloxone availability (Correal, 2018;
Evoy et al., 2018; Lozo et al., 2019; Meyerson et al., 2018; Puzantian & Gasper, 2018; Sisson et
al., 2019).
Third, the research methodology was a strength. Using a simulated client methodology
provides real-world insight into naloxone access from the point of view of a person in need of
naloxone. It also removes Hawthorne effect biases from respondents and simulates the results
that a Georgia resident would experience when attempting to access naloxone across the state.
Lastly, this study provided an opportunity to investigate naloxone availability during a
public health pandemic. While this was not intended during study conception and design, it does
provide insight on naloxone availability during a pandemic. Naloxone availability continues to
be crucial, as more than 40 states have shown increases in opioid deaths during the COVID-19
pandemic (American Medical Association, 2020). Preliminary research showed that opioid
overdoses have risen across the country, with increases in the use of cocaine, fentanyl, heroin,
and methamphetamines (Ochalek et al., 2020; Slavova et al., 2020; Wainwright et al., 2020),
particularly with increased risk for black residents (Ochalek et al., 2020; Wainwright et al.,
2020). In Georgia, preliminary reports showed a 25.3% increase in opioid-involved overdose
deaths and larger increases in heroin-involved (32.3%) and fentanyl-involved (61.4%) overdose
deaths (Georgia Department of Public Health, 2020b).
Although this study has many strengths, limitations are present. First, in conducting the
survey, data collectors did not differentiate between speaking with pharmacists and pharmacy
staff. The staff member answering the phone was surveyed to gather information about naloxone
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availability. The reason for this approach was to simulate resident interaction with either
pharmacists or pharmacy staff closely. Also, because pharmacy staff are trained, they should be
aware of any state policies, orders, or laws that impact pharmacy practice. This study also did not
seek to assess pharmacists’ or pharmacy staff members’ knowledge, attitudes, and beliefs about
naloxone dispensing. This could affect whether a pharmacy stocks naloxone and is willing to
dispense it under Georgia’s standing order. Previous research has shown that pharmacists’
knowledge, attitudes, and beliefs can negatively affect naloxone access and dispensing (Bailey &
Wermeling, 2014; Hammett et al., 2014; Puzantian & Gasper, 2018; Raisch et al., 2005; Sisson
et al., 2019; Zaller et al., 2013). More research is needed to identify any barriers of this kind in
Georgia.
Second, the study design was a cross-sectional one, providing information at one point in
time. Thus, causality cannot be established. No data is available to accurately describe naloxone
availability across Georgia before standing order implementation. There is no way to determine
availability before standing order implementation, which would have provided a baseline for
comparison. However, results have been put into context based on previous research in Georgia
and other states.
Third, data limitations were prevalent in this study. Results may not be generalizable
because this study focuses only on a single state. Georgia Board of Pharmacy Roster information
was not accurate. Pharmacy data were misclassified, as some hospice locations were listed as
retail, some counties were not correctly listed, and some pharmacies had address located outside
of the state. Data collectors attempted to correct information during survey administration. This
included noting correct county locations while verifying addresses, noting if a pharmacy was
located outside of Georgia, and noting if it was not a community retail pharmacy. Additionally,
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the non-statutory variables included in this study were county-level, which may be too broad in
assessing true associations with naloxone availability. The political leaning variable may have
also missed associations, as it was noted as a binary variable instead of a continuum of political
leanings and preferences.
Last, there are additional limitations to consider related to the complexity of the
epidemic, which poses a challenge in predicting naloxone availability across the state. With this
complexity, there is a possibility that significant variables were omitted that could impact
naloxone availability. This study did produce a statistically significant model to predict naloxone
availability. However, the model could be improved by including additional variables that could
impact naloxone availability. Prevention efforts related to the opioid overdose epidemic
involves stakeholders at all levels (individual, community, organizationally, and culturally).
Also, naloxone is provided outside of pharmacies, and the use of these non-pharmacy sources
was not examined.
Implications for Policy Implementation and Practice
Little research has been published on associations between standing orders, naloxone
availability, and pharmacy and community-level factors (Guadamuz, Alexander, Chaudhri,
Trotzky-Sirr, & Qato, 2019; Lozo, Nelson, Ramdin, & Calello, 2019; Meyerson et al., 2018).
The Policy Implementation Framework provides a way to identify and assess factors critical to
the policy implementation process (Sabatier & Mazmanian, 1980). The conceptual framework
for this study identified variables that could influence implementation of Georgia’s standing
order. As this study showed, factors that may prove to be important in successful policy
implementation in one context may not influence successful policy implementation in others. For
example, in this study, county median household income, urbanicity/rurality, and opioid
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overdose death rates were not statistically significant, but research has shown them to be
associated with naloxone availability. The literature has posited factors significant in improving
naloxone availability – but put into different contexts, in various states, and for other populations
– these factors may not be consistently significant.
Researching policy implementation using the Policy Implementation Framework also
provides a way to distinguish and group variables by determining whether they can be
manipulated or controlled by policy makers as a law is being enacted (statutory variables) from
those that cannot be manipulated but are important to policy implementation (tractability and
non-statutory variables). In this study, two of the variables in the non-statutory variable group,
were statistically significant in predicting naloxone availability. This study shows that pharmacy
type and political leaning are associated with and are statistically significant predictors of
naloxone availability. These variables, along with the other variables included in the study, were
able to produce a statistically significant model to predict compliance with the standing order.
Although these results may not be generalizable to other states, they provide insight into groups
of factors that can predict availability. Results also offer additional insight into variables
previously positioned in the literature as associated with naloxone availability. This framework
highlighted a novel predictor to consider in assessing policies related to naloxone access and
availability: political leaning.
Another consideration of this research is the affect public health emergencies and
pandemics may have on policy implementation. In this study, availability has continued to
increase (compared to previously reported availability) despite the current response to a global
pandemic. The opioid epidemic continues to be a public health issue for communities across the
country and the world. Considering the impacts currently seen with the COVID-19 pandemic on
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other health issues, it is more important than ever to consider factors that could affect successful
public health policy implementation. During the pandemic, opioid overdoses have continued to
rise. Those with limited access to treatment due to the pandemic would benefit most from access
to naloxone through community pharmacies. While little research has been published to discuss
the relationship between limited access to naloxone due to COVID-19 and opioid overdoses and
deaths, preliminary literature has uncovered impacts and rising opioid overdoses and deaths due
to changes in treatment provision, increases in risk factors, and lack of access to treatment
(Georgia Department of Public Health, 2020b; Ochalek et al., 2020; Slavova et al., 2020;
Wainwright et al., 2020).
This framework can be a useful tool for practitioners and policymakers in structuring
successful policy implementation and determining factors that could influence success at any
point in the policy implementation process.
Recommendations and Future Research
This research offers some insight into implications for public health practice and future
research. One practice recommendation is to develop a centralized database on naloxone
distribution to include information on where naloxone is dispensed across that state. This
database could leverage existing systems used by states or could be created to include more
detailed information. Some states currently utilize prescription drug monitoring programs to
track naloxone dispensing, which provides more complete data on when and where naloxone is
prescribed and dispensed. This system could be useful to Georgia since it provides access to
pharmacists to include dispensing data for controlled substances. Other states and localities have
used other platforms such as the Overdose Detection Mapping Application Program (ODMAP)
to collect data from first responders about fatal and non-fatal suspected overdoses, in addition to
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naloxone administration. Additionally, there are still organizations outside of prescribers,
dispensers, and first responders that provide naloxone to communities. Pharmacies are just one
of the sources through which naloxone is distributed, but it remains a primary source for many.
Employing qualitative research to investigate in more detail factors that drive successful
policy implementation would add context to the findings of this study. Several opportunities
exist for future research, including examining pharmacy and community-level characteristics to
ensure wider implementation of standing orders in states. Future research of naloxone
availability should focus on evaluating and examining the impact of pharmacists’ and pharmacy
staff knowledge attitude and beliefs on naloxone availability in Georgia; analysis of the distance
of each pharmacy from a hospital to determine whether stocking and dispensing are influenced
by access to care and distance from care, and social capital and its relationship with a
community’s likelihood to stock naloxone. Additional research can also be conducted to identify
the impact of policy preferences on the policy implementation process.
Additionally, more research is needed to investigate the influence of political preferences
on successful naloxone implementation. As of this writing, no information has been shared in the
literature about naloxone availability and political preferences. Results from this study
demonstrate that these preferences can and do influence naloxone availability.
Conclusion
Overall, descriptive statistics show that availability has increased compared to available
statistics from recently published studies. Chi-square and multiple logistic regression analyses
demonstrate that pharmacy type and county political leaning are both associated with and are
statistically significant predictors of naloxone availability. Opportunities remain to better
understand successful policy implementation and the statutory, non-statutory, and tractability
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variables that influence the process. Several opportunities exist for future research, including
examining pharmacy characteristics that impact the wider implementation of standing orders in
states and examining communication about availability with potential consumers. Results from
this study can be used to improve naloxone policy implementation and better understand
successful outcomes.
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APPENDIX B
SURVEY INSTRUMENT
The table below includes survey tool information. This information will be used to populate the
data collection tool. Field labels, descriptions, survey questions, form attributes, and information
studies are included. Field numbers marked with an asterisk (*) note questions that will be asked
to pharmacy staff directly. Other fields will be used to gather information about the interaction.
Field
#

Field Label

Field Description
(Notes for
collection)

Field text/Question

1

record_id

Record ID
number

Record ID

2

full_name

Name of
pharmacy

Pharmacy Name

3

phone

Pharmacy phone
number

Phone

4

addr_line1

Pharmacy address

Address

5

county

Pharmacy county

County

6

city

Pharmacy city

Pharmacy City

Form Attributes
Automatically generated
based on sampled list.
This will link pharmacy
name/location to sample
listing.
Pre-populated with
information from
Georgia Board of
Pharmacy roster. Will be
removed after data
collection and before
data analysis.
Populated based on
address information
from Georgia Board of
Pharmacy roster. Will be
removed after data
collection and before
data analysis.
Pre-populated with
information from
Georgia Board of
Pharmacy roster.
Includes number and
street name from roster.
Will be removed after
data collection and
before data analysis.
Pre-populated with
information from
Georgia Board of
Pharmacy roster. Will be
used for data analysis.
Dropdown (populated
based on address

Informing Study
(if applicable)

-

-

-

-

-

-
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7

8

9

10*

11*

12

13*

information from
Georgia Pharmacy List)
Dropdown:
1– answered my inquiry
immediately
2 – transferred me to
another staff member
3 – put me on hold then
handled my inquiry
(within 5 minutes)
4 – left me on hold and
did not return (more than
5 minutes)
5 – asked me to call
back
6- asked if they could
call me back (decline
call back)
7 – other (enter any
notes that do not fit any
of the first 6 options)

staff1

Notes on how call
was handled

Which of the
following did the
staff member do?

staffother1

Additional notes
for how pharmacy
staff handled the
call

7– Other description

text

-

-

Were you able to
speak with a
pharmacy member
about Narcan?
(If no – end record)

Dropdown:
0 – no (record)
1 – yes

-

-

“I’m calling to find
out if I can get
Narcan. Do you
have Narcan nasal
spray available?”

Dropdown:
1 – no, not today (see
#11)
2 – no, we don’t sell it
3 – yes
4 – other (specify)

-

“If I can’t get it
today, can you order
it?”

Dropdown:
1 – Yes (see #13)
2 – No
3 – Other

(Evoy et al., 2018)

Text
(specify as
communicated by
pharmacy staff)

-

Dropdown:
1 – less than 24 hours
2 – 24 – 48 hours
3 – more than 48 hours

-

pharm1

sellna

sellna_notoday

sellna_other

-

Specify other

Sellna_yes

Notes about how
long it will take to
order.

“How long will it
take to order and get
to the pharmacy?”

-

(Egan, 2019; Evoy et
al., 2018; Puzantian
& Gasper, 2018)
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14*

naworx

Did the staff
member indicate
they would sell
naloxone without
a prescription
from a doctor?

“I do not have a
prescription from a
doctor, is that ok?”

Dropdown:
0 – no
1 – yes
3 – other (specify)

(Egan, 2019)

Text
(specify as
communicated by
pharmacy staff)

-

15

naworx_other

-

Specify “other”

16*

costna

-

“How much does
Narcan cost?”

17*

typena

-

“Are there different
options available?”

18

typena_other

-

Specify “other”

(Egan, 2019;
Puzantian & Gasper,
2018)
checkbox
1 – typena1 (Narcan prefilled syringe)
2– typena2
(intramuscular/injection)
3 – typena3 (EVZIO,
auto-injector)
4 – other
Text
(specify as
communicated by
pharmacy staff)

(Egan, 2019)

-
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APPENDIX C
TOLERANCE AND VIF VALUES

Variable

Tolerance Value

Variance Inflation Factor (VIF)

Pharmacy type

.963

1.038

County urbanicity

.607

1.649

Opioid overdose death rate

.871

1.148

Household income

.655

1.527

Political leaning

.743

1.346
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APPENDIX D
COLLINEARITY MATRIX

Variable

1

1. Pharmacy Type

–

2

3

4

2. County Urbanicity

-.077

–

3. Opioid Overdose Death Rate

.015

-.039

–

4. Household Income

.074

.479

-.249

–

5. Political Leaning

.046

.332

.281

-.099

5

–

